

CURRICULUM VITAE
Salvatore Oddo, PhD

February 20, 2020

PERSONAL

HOME ADDRESS: 1222 East Squawbush Pl
Phoenix, AZ 85048

HOME TELEPHONE: 210-8585994

BUSINESS ADDRESS: Neurodegenerative Disease Research Center
Biodesign Institute
School of Life Sciences
Arizona State University
1001 S. McAllister Ave
Tempe, AZ 85287

BUSINESS TELEPHONE: (480)727-3490

E-MAIL ADDRESS: oddo@asu.edu

BIRTHPLACE: Siracusa, Italy

CITIZENSHIP STATUS: Italian
American

EDUCATION AND TRAINING: (Chronological order)

UNDERGRADUATE SCHOOL	DATES MONTH/YEAR	DEGREE/YR/SUBJECT
University of Catania Italy	09/1993- 7/1999	BS 1999, Molecular Biology First class honors degree
GRADUATE/PROFESSIONAL SCHOOL		
University of California Irvine, CA	09/2003 – 07/2005	PhD, 2005, Neurobiology & Behavior

Signed: Salvatore Oddo Dated: February 20, 2020

POSTDOCTORAL FELLOWSHIP EXPERIENCE

Postdoctoral Researcher, University of California, Irvine, CA
Department of Neurobiology and Behavior

07/2005 – 07/2007

ACADEMIC HONORS AND AWARDS

Merit Scholarship from University of Catania (Italy)	12/2018
Al Nichols Research Prize in the Neurobiology of Aging for outstanding contributions to the study of brain aging	07/2018
McGaugh Award for Excellence in Graduate Research in Neurobiology & Behavior, University of California Irvine	05/2013
Ralph W. Gerard award for Excellence in the History of Neuroscience. University of California Irvine	11/2011
Irvine Medal Fellowship for Excellence in Graduate Research. University of California Irvine	07/2011
AD/PD Award (Alzheimer's Disease and Parkinson's Disease) in Memory of Roberto Cornelli for Young Scientists presenting their work at the AD/PD meeting in Sorrento, Italy 2005	10/2010
Travel Fellowship from the Alzheimer's Association to attend the 10th International Conference on Alzheimer's Disease and Related Disorders, Madrid, Spain	08/2009
Dean's Award for Postdoctoral Research Excellence, University of California Irvine	05/2009
University Research Council Grants Program Award, University of Texas Health Science Center at San Antonio	01/2006
The Nathan Shock New Investigator Award assigned by the Gerontological Society of America in recognition of innovative and influential publications	01/2006
Rising Stars Award from The Board of Regents of the University of Texas. This award included a grant for \$250,000.00 for equipment expenditures	05/2005
The Glenn Award for Research in Biological Mechanisms of Aging. This award included a grant for \$60,000.00	03/2005
The Presidential Distinguished Junior Research Scholar Award from the University of Texas Health Science Center at San Antonio	02/2005
New Vision Award from the Charleston Conference on Alzheimer's disease	08/2004
Permanent member of the Cellular and Molecular Neurodegeneration Study Section	06/2004
Edson Endowed Professor in Dementia Research	01/1992

APPOINTMENTS (Chronological order)

ACADEMIC

Assistant Researcher, University of California, Irvine, CA Department of Neurobiology and Behavior	07/2007- 06/2008
Assistant Professor, University of Texas Health Science Center Department of Physiology, San Antonio, Texas	07/2008 -06/2013
Senior Scientist, Banner Sun Health Research Institute Sun City, AZ	07/2013- 08/2015
Associate Professor, University of Arizona College of Medicine Department of Basic Medical Sciences, Phoenix, AZ	07/2013 - 08/2015
Adjunct Associate Professor, University of Arizona College of Medicine, Department of Basic Medical Sciences, Phoenix, AZ	08/2015 - 06/2019
Director of the Interdisciplinary Graduate Program in Neuroscience Arizona State University, Tempe, AZ	07/2017 - 06/2019
Associate Professor, Arizona State University, School of Life Sciences, Tempe, AZ	08/2015- present

PROFESSIONAL ACTIVITIES

EDUCATIONAL

Internship in Molecular Biology at University of Catania, Italy	07/1999 – 11/1999
Staff Research Associate, University of California, Irvine, CA	11/1999 - 08/2002
Graduate Student Researcher, University of California, Irvine, CA	09/2002 – 07/2005
Alzheimer’s Drug Discovery Foundation Review Board Member	2011-present
Internal Scientific Advisory Committee Member for the Arizona Alzheimer’s Consortium	2013-present
Permanent Member of the NIH Cellular and Molecular Neurodegeneration Study Section	2018-present

TEACHING

COURSE-BASED TEACHING:

Institution: Arizona State University

Course Name	Level	Role	Date
Cellular and Molecular Biology (Neu555)	Graduate	Instructor	08/2018 – 12/2018

Number of students: 28. Three credits. This course covers basic aspects of cellular and molecular biology.

Cellular and Molecular Biology (BIO476) Undergraduate Instructor 08/2018 – 12/2018
Number of students: 54. Three credits. I developed this course in 2017. It covers basic cellular and molecular mechanisms related to cell biology of neurons, neuronal development, electrical properties of neurons

Topics in Neuroscience (BIO400) Undergraduate Instructor 01/2018 – 05/2018
Number of students: 21. Three credits. I have independently developed this course, which was offered for the first time in the spring semester of 2016. The course covered age-dependent neurological diseases (or a specific aspect of a disease).

Undergraduate Instructor 11/2017 -12/2017
Recitation (BIO189)
Number of students: 19. One credit. This is a five weeks recitation course during which students were exposed to basic molecular, biochemical, and behavioral techniques in my laboratory.

Cellular and Molecular Neuroscience Undergraduate Instructor 08/2017 -12/2017
(BIO476)
Number of students: 31. Three credits. I have independently developed this course, which is part of the new Neuroscience co-major at ASU. The course covers basic cellular and molecular mechanisms related to cell biology of neurons, neuronal development, electrical properties of neurons.

Pathologies of the Aging Brain (BIO498) Undergraduate Instructor 01/2017 – 05/2017
Number of students: 11. Three credits. I have independently developed this course, which was offered for the first time in the spring semester of 2016. The course covered age-dependent neurological diseases (or a specific aspect of a disease).

Neurobiology (BIO467) Undergraduate Instructor 08/2016 – 12/2016
Number of students: 59. Three credits. This course explores the nervous system across many levels (genetic, molecular, cellular, and network). Using an active learning approach, I emphasize critical thinking and problem-solving in all evaluation exercises, including daily class participation.

Pathologies of the Aging Brain (BIO498) Undergraduate Instructor 01/2016 – 05/2016
Number of students: 27. Three credits. I have independently developed this course, which was offered for the first time in the spring semester of 2016. The course covered age-dependent neurological diseases (or a specific aspect of a disease).

Institution: University of Arizona, College of Medicine-Phoenix

Course Name	Level	Role	Date
Case-based instruction: Cardiovascular	Medical School	Instructor	02/2014 – 03/2014
<i>Number of students: 8. Case-Based Instruction (CBI) is a teaching modality using a clinical case-based scenario. CBI provides the opportunity for students to learn new material while also applying previously learned material. CBI is extremely student-centric. CBI should develop and hone critical thinking skills, encourage discovery and identify gaps in student knowledge.</i>			

Institution: University of Texas, Health Science Center at San Antonio

Course Name	Level	Role	Date
Molecular Physiology (6091-05)	Graduate	Course Director	01/2012 – 06/2013

This course provides students with the most up-to-date knowledge on the current understanding of second messengers and signaling cascades in neurons.

Neurobiology (INTD 7002): Learning and memory section	Graduate	Course Director	01/2012 – 06/2012
---	----------	-----------------	-------------------

Overall student contact hours: 16. Total number of student enrolled: 2. I have independently developed this course, which was offered for the first time in the spring semester of 2012. This course focuses on recent findings and topics related to the underlying aspects of the neural basis of learning and memory

Fundamentals of Biomedical Sciences (INTD 5000)	Graduate	Instructor	12/2010 – 06/2013
---	----------	------------	-------------------

Overall student contact hours: 22. In 2012, I was a lecturer and gave 3 lectures of 1 hour each. In 2011 and 2012, in addition to lecturing, I was the team leader for week 6 of the course. Total number of students enrolled: 122. My responsibilities were to develop the lecture content for the week by coordinating with other team members and to lecture.

Neurobiology of Aging (CSBL 6058)	Graduate	Instructor	01/2010 – 06/2013
-----------------------------------	----------	------------	-------------------

Overall student contact hours: 16, 8 hours in 2010 and 8 in 2011. Total number of student enrolled: 9. This course focuses on recent findings and topics related to the underlying pathology of aging in the nervous system and the relationship of aging to neurodegenerative disease.

Seminar (PHYL 6090)	Graduate	Course Director	09/2009 – 06/2013
---------------------	----------	-----------------	-------------------

Overall student contact hours: 36 in class format plus 76 in presentation format. Total number of student enrolled: 128. The goal of this course is to teach students the basics of oral presentations. Students are required to give an oral presentation of their data in a formal setup. Additionally, formal class lectures are given to criticize and improve slide generation and presentation techniques. The course is offered twice a year.

Molecular, Cellular and Developmental Neuroscience (INTD 5040)	Graduate	Instructor	01/2009 – 05/2011
--	----------	------------	-------------------

Overall student contact hours: 21; 6 hours in 2009; 8 hours in 2010; 7 hours in 2011. Total number of students enrolled: 46. This course is intended to introduce students to a broad survey of the basics of molecular, cellular and developmental neuroscience. Current topics and concepts are discussed in discussion sessions that include student participation.

Molecular and Pharmacological Basis of Therapeutics (PHAR 6020)	Graduate	Instructor	06/2009 – 12/2011
---	----------	------------	-------------------

Overall student contact hours: 9; 3 hours in 2009, 3 hours in 2010, 3 hours in 2011. This course provides the graduate student with current knowledge of how genetic variants can affect drug response and the potential to optimize drug therapy. Class format includes lectures, discussion of selected literature, individual student presentations, and the opportunity for the development of a mini pharmacogenetic/genomic protocol and consent form to address a clinical/biomedical question.

Biology of Aging (CSBL 6048) Graduate Instructor 05/2010 - 05/2010
Overall student contact hours: 3; Total number of student enrolled: 10. The purpose of this course is to provide students with the most up-to-date information on the current understanding of the aging process. This advanced interdisciplinary graduate course provides an experimental understanding of the interrelated areas of aging and age-related diseases.

Institution: University of California, Irvine

Course Name	Level	Role	Date
Molecular Neuroscience (BIO 206)	Graduate	Instructor	10/2007 - 05/2008
<i>Overall student contact hours: 18; This course reviews molecular and cellular mechanisms involved in neuronal function, including control of gene expression, post-transcriptional and post-translational processing, RNA and protein targeting, cell death mechanisms, and the molecular genetic basis of neurological disorders. Overview of the molecular aspects of developmental neurobiology is also included.</i>			
Neurobiology Laboratory (BioSci 113)	Undergraduate	Instructor	11/2003 - 04/2004
<i>Overall student contact hours: 27. This is a neurobiology laboratory course in which students conduct weekly experiments covering several aspects of basic functions of the nervous system.</i>			

Institution: University of Coimbra, Portugal

Course Name	Level	Role	Date
Doctoral Programme in Experimental Biology and Biomedicine	Graduate	Guest Lecturer	02/2007 - 02/2007
<i>Overall student contact hours: 10. This course focuses on the latest research in the field of neurodegenerative diseases, focusing on Alzheimer disease (AD), Parkinson disease (PD) and Huntington disease (HD).</i>			

OTHER TEACHING:

Post Spring ASU Global Intensive Experience in Neuroscience –London, UK May 2018
 This is an ASU faculty-directed study abroad program proposal focused on The Neuroscience of Sustainable Brain Plasticity at King’s College London. Dr. Brian Smith and I are the directors of this initiative and traveled to the United Kingdom in May with eight ASU students enrolled in the Neuroscience concurrent major. The program lasted ten days, during which students learned about the aging of the human brain.

POST-DOCTORAL FELLOWS AND OTHER SCIENTISTS SUPERVISED

Post-Doctoral Supervision

Name	Institution	Date
Emily Turner, Ph.D. Dr. Turner was a Postdoctoral Fellow in my laboratory. Currently, she is working on assessing the role of necroptosis in Alzheimer’s disease.	Arizona State University	06/2017 – 06/2019
Rasika Vartak, Ph.D. Dr. Vartak was a Postdoctoral Fellow in my laboratory. Currently, she is working on assessing the role of S6K1 on tau.	Arizona State University	12/2016 – 06/2019
Ramon Velazquez, Ph.D. Dr. Velazquez was a Postdoctoral Fellow in my laboratory. His project focuses on assessing whether diet-induced epigenetic changes in a mouse model of AD are transmitted from generation to generation.	Arizona State University	09/2014 – 06/2019

Caterina Branca, Ph.D. Arizona State University 02/2014 - 02/2018
Dr. Branca was a Postdoctoral Fellow in my laboratory. She studied the role of RIPK1 in Alzheimer's disease.

Rizwan Haque, Ph.D. Arizona State University 11/2016 – 05/2017
Dr. Haque was a Postdoctoral Fellow in my laboratory. His project was focused on identifying the molecular mechanisms leading to hyperactive mTOR in Alzheimer's disease.

Joshua Talboom, Ph.D. Arizona State University 06/2014 – 12/2015
Dr. Talboom was a Postdoctoral Fellow in my laboratory. He is using innovative approaches to restore cognition in a mouse model of Alzheimer's disease by remotely stimulating selective neuronal networks. Currently, Josh is a postdoctoral fellow in the laboratory of Dr. Matt Huentelman at the Translational Genomics Institute in Phoenix.

Emma Farrell, Ph.D. BSHRI 02/2014 – 10/2014
Dr. Farrell was a Postdoctoral Fellow. Her project focused on using pharmacological approaches to reduce mTOR signaling in Alzheimer's disease. Currently, she is a Chemistry Lecturer at Arizona State University West.

Miranda Orr, Ph.D. UTHSCSA 04/2012-12/2013
Dr. Orr was a Postdoctoral Fellow in my laboratory. The goal of her project was to determine whether facilitating endogenous compensatory mechanisms in the brain might improve learning and memory deficits in Alzheimer's disease. Currently, she is an Instructor in the Department of Pharmacology at the University of Texas Health Science Center at San Antonio and a Scientist at the Veteran Affairs Hospital in San Antonio.

Monica Maldonado, Ph.D. UTHSCSA 06/2010-12/2011
Dr. Maldonado was a Postdoctoral Fellow in my laboratory. The goal of her project was to elucidate the role of chaperone-mediated autophagy in A β and tau accumulation. Currently, she is an Editor for the American Journal Experts.

Employee Supervision

Name	Institution	Date
Karen Kibler	Arizona State University	07/2019 - Present
Chaya Fux	Arizona State University	12/2018 - Present
Austin Vural	Arizona State University	11/2018 – Present
Annika Decker	Arizona State University	08/2018 - Present
Alexis Rodin	Arizona State University	10/2016 – Present
Wendy Winslow	Arizona State University	02/2016 – Present
Mario Moreno	Arizona State University	08/2015 – 01/2016
Eric Ferreira	BSHRI/Arizona State University	02/2015 – 05/2019
Aaron Walter	BSHRI	09/2014 – 07/2015
Darren Shaw	BSHRI	09/2013 – 08/2015
Lauren Hartman	BSHRI	09/2013 – 09/2014
Laura Nelon	UTHSCSA	03/2012 – 10/2012
Smita Majumder	UTHSCSA	11/2008 – 08/2012

GRADUATE STUDENTS SUPERVISED

Name	Institution	Date
Sara Knowles Sara is a Neuroscience Ph.D. student. Her project focuses on identifying the role of RIPK1 in Alzheimer's disease	Arizona State University	08/2017 – present
Lynette Bustos Lynette was a Neuroscience Ph.D. student. She studied the interaction between ApoE4 and tau.	Arizona State University	08/2017 – 07/2019
Alexis Rodin Alexis was a Masters' student. She studied the role of cell cycle re-entry in Alzheimer's disease.	Arizona State University	08/2017 – 07/2019

Visiting graduate students

Name	Institution	Date
Ramona Belfiore Ramona's was an Italian Graduate Student. She came to my lab at ASU to study the progression of Alzheimer's disease-like pathology in 3xTg-AD mice.	Arizona State University	04/2016 – 03/2019
Caterina Branca Caterina was a graduate student at the University of Brescia, Italy. She joined my laboratory in summer of 2013 for completing a project as part of her Ph.D. studies and focused on understanding the relationship between β -blockers and Alzheimer's disease. After graduating, she joined my lab as a Postdoctoral Fellow.	UofA COMP	09/2013 - 02/2014

Dissertations Directed for graduate students

Name	Institution	Date
Antonella Caccamo Antonella enrolled in the international Ph.D. program at the University of Catania, Italy. She performed her thesis in my laboratory, which focused on elucidating the role of mTOR Alzheimer's disease. Currently, she is an Assistant Research Professor in the Biodesign Institute.	University of Catania, Italy	08/2012 – 07/2016
Elena Wisely Elena joined my laboratory in 2011 as an MD/Ph.D. student. The goal of her project was to elucidate the role of β 2 adrenergic receptors in the pathogenesis of Alzheimer disease. She defended her thesis and graduated on March 2014. She has since completed her MD, and she is currently a pathology resident at UT Southwestern in Dallas.	UTHSCSA	07/2011-04/2014
David Medina David Medina joined my laboratory in 2008 for his graduate studies. He defended his Ph.D. thesis, which focused on elucidating the molecular link between progranulin and TDP-43 accumulation. He graduated on July 31, 2013. Currently, David is a scientist in the laboratory of Dr. Robert Bowser at the Barrow Neurological Institute in Phoenix.	UTHSCSA	11/2008-07/2013

Qualifying Exam Committee for graduate students

Name	Institution	Date
Jennifer Parrott	UTHSCSA	06/2012 – 09/2012

Jennifer was a Ph.D. student in the laboratory of Dr. Jason O'Connor, Department of Pharmacology. Title: Modulating the balance of kynurenine pathway metabolites to attenuate Alzheimer's disease comorbid depressive-like behaviors, neuropathology, and cognitive decline.

Danielle Victor UTHSCSA 04/2012 - 04/2012
Danielle was an MD/Ph.D. student in the laboratory of Dr. Brian Herman, Department of Cellular and Structural Biology/Barshop Institute for Longevity and Aging Studies. Title: Peroxynitrite induces mitochondrial protein nitration and dysfunction in the aging heart.

Teresa Evans UTHSCSA 02/2011 - 03/2011
Teresa was a Ph.D. student in the laboratory of Dr. Holly Van Remmen, Department of Cellular and Structural Biology/Barshop Institute for Longevity and Aging Studies. Title: Cell and disease-specific modulation of autophagy following traumatic brain injury.

Rene Santacruz UTHSCSA 04/2010 - 07/2010
Rene was a Ph.D. student in the laboratory of Dr. Senlin Li, Department of Medicine.

Rotation Graduate Student Supervision

Name	Institution	Date
Sara Knowles	Arizona State University	08/2017 – 10/2017
During her rotation as first-year Ph.D. student in the Neuroscience program, Sara learned how to test cognitive function in mice.		

Lalitha Venkataraman	Arizona State University	05/2014 – 07/2014
During her rotation as first-year Ph.D. student in the Neuroscience program, Lalitha assessed the degree of TDP-43 pathology in a new mouse model of FTL D.		

Rene Solano Fonseca	UTHSCSA	11/2012 – 12/2012
During his rotation, Rene learned how to perform stereotaxic injection into the mouse brain.		

Brian Stoveken	UTHSCSA	09/2012 – 11/2012
During his rotation, Brian conducted immunohistochemical experiments to map the regional and temporal progression of A β and tau pathology in a mouse model of Alzheimer's disease.		

Juan Xiong	UTHSCSA	02/2012 – 03/2012
During her rotation, Juan learned basic cell culture techniques.		

Paul Anthony Martinez	UTHSCSA	01/2012 – 02/2012
During his rotation, Anthony learned how to use the Freeze Monitor to conduct contextual fear conditioning experiments. Currently, he is a Ph.D. student in the laboratory of Dr. Randy Strong, Department of Pharmacology		

Shauna Hill	UTHSCSA	11/2011 – 12/2011
During her rotation, Shauna worked with David Medina, a graduate student in the laboratory, to establish the effect on increasing mitochondrial function on Alzheimer's disease pathogenesis.		

Saul Jaime UTHSCSA 09/2011 - 11/2011
During his rotation, Saul learned how to slice a mouse brain and perform immunohistochemical experiments. He was a first-year Ph.D. student in the IMGP program.

Rebekah Mahoney UTHSCSA 09/2010 - 11/2010
During her rotation, Rebekah learned how to perform PCR and Western blot experiments. Rebekah was a second year Ph.D. student in the laboratory of Dr. Benjamin Eaton, Department of Physiology.

Elena Wisely UTHSCSA 05/2010 - 07/2010
During her rotation in my laboratory, Elena learned how to perform Western blot experiments. She was a second-year MD/Ph.D. student in my laboratory.

Walter Holbein UTHSCSA 11/2009 - 12/2009
During his rotation, Walter learned how to perform intracranial injections in mice. Walter was a PhD student in the laboratory of Dr. Glenn Toney, Department of Physiology.

Chrislie Starr UTHSCSA 11/2009 - 12/2009
During her rotation, Chrislie learned how to extract proteins from the mouse brain. She also learned how to perform Western blot experiments.

Celest Austin UTHSCSA 07/2009 - 08/2009
During her rotation, Celest learned how to purify RNA from mouse brain and perform qPCR. She did her Ph.D. thesis in the laboratory of Dean David Weiss, Department of Physiology.

Daniel Pulliam UTHSCSA 01/2009 - 02/2009
During his rotation, Daniel learned how to perform Western blot experiments. He did his Ph.D. thesis in the laboratory of Dr. Holly Van Remmen.

David Medina UTHSCSA 11/2008 - 12/2009
David rotated in my laboratory for two different periods, 11/2008-12/2008 and 02/2009-04/2009. During these rotations, David learned how to extract proteins from the mouse brain, how to perform western blot experiments and how to prepare primary neuronal culture.

Dissertation Proposal Committee for graduate students

Student	Institution	Date
Lalitha Venkataraman	Arizona State University	08/2015 – 12/2018
Lalitha is a PhD student in the laboratory of Dr. Michael Sierks. The goal of her dissertation proposal is to develop new conformation-specific antibodies for neurodegenerative diseases.		

Teresa Evans	UTHSCSA	09/2012 – 06/2013
Teresa was a Ph.D. student in the laboratory of Dr. Holly Van Remmen, Department of Cell and Structural Biology/Barshop Institute for Longevity and Aging Studies. The goal of her dissertation proposal was to assess the role of traumatic brain injury in amyotrophic lateral sclerosis.		

Wenrui Ye	UTHSCSA	09/2012 – 06/2013
Wenrui was a Ph.D. student in the laboratory of Dr. Brent Thompson. The goal of her dissertation proposal was to examine disturbance in the fetal serotonergic nervous system induced by MNR, which may predispose the offspring to the psychiatric disorders reported in IUGR offspring.		

Yael Edrey UTHSCSA 03/2011 - 04/2012
Yael was a Ph.D. student in the laboratory of Dr. Rochelle Buffenstein, Department of Physiology/Barshop Institute for Longevity and Aging Studies. She successfully defended in April 2012. Title: The longest-living rodent as a model for neurodegeneration and Alzheimer's disease.

Yu Tao UTHSCSA 07/2009 – 11/2012
Yu Tao was a Ph.D. student in the laboratory of Dean David Weiss. She successfully defended on November 2012. Title: Defining the role of GABAergic transmission in neurogenesis in adult brain.

Leo Chang UTHSCSA 03/2009 – 12/2012
Leo was a Ph.D. student in the laboratory of Dr. Benjamin Eaton in the Department of Physiology. He successfully defended in December 2012. Title: Molecular characterization of DARF2 in the Drosophila nervous system.

Si-Eun Yoo UTHSCSA 03/2009 - 08/2011
Si-Eun obtained a Master of Science in August 2011. Title: New insights into the in vivo role of lipid peroxidation in adult mice using novel Gxp4 knockout mouse model.

UNGRADUATE STUDENTS SUPERVISED

Undergraduate Honors Thesis, Primary Mentor and Chair

Student	Institution	Date
Likith Surendra	Arizona State University	08/2017 – present
Likith joined my laboratory in his sophomore year and has worked in the lab under my supervision since. His project is focused on dissecting the role of PRAS40 in learning and memory.		

An Tran	Arizona State University	08/2015 – 08/2018
An joined my laboratory in her sophomore year and has worked in the lab under my supervision since. Her project is focused on identifying the role of tau in the adult brain. She defended her honors thesis on April 12 th , 2018.		

Prakriti Shukla	Arizona State University	08/2015 – 08/2018
Prakriti joined my laboratory in her sophomore year and has worked in the lab under my supervision since. Her project is focused on dissecting the role of S6K1 in old 3xTg-AD mice. She defended her honors thesis on March 22 nd , 2018.		

Patrick Sarette	Arizona State University	08/2015 – 08/2018
Patrick joined my laboratory in his sophomore year. In January 2018, he successfully defended his honors thesis, titled “Elucidating the Effects of PRAS40 on Learning and Memory”. He has been accepted into the University of Arizona, College of Medicine, Phoenix Medical School and started in July 2018.		

Undergraduate Honors Theses, Committee Member

Student	Institution	Date
Justin Palmer	Arizona State University	05/2016 – 12/2017
Justin was an undergraduate student enrolled in Barrett, The Honors College. I served as a co-chair of his dissertation committee together with Dr. Bimonte-Nelson. Currently, he is a graduate student at University of Arizona.		

Jason Ma Arizona State University 01/2017 – 05/2017
Jason was an undergraduate student enrolled in Barrett, The Honors College. His primary mentor was Dr. Brian Smith. I served as a member of his dissertation committee

Other Undergraduate Students Supervised

Student	Institution	Date
Christopher Negrich	Arizona State University	08/2015 – 12/2016

Chris' project was to determine the biochemical changes in 3xTg-AD mice following traumatic brain injury.

Owen Steinwall	BSHRI	06/2014 – 08/2014
----------------	-------	-------------------

Owen joined my laboratory as an intern during summer. His project was to quantify the regional and temporal progression of A β and tau pathology in 3xTg-AD mice.

Angelica Salinas	UTHSCSA	06/2012 – 06/2013
------------------	---------	-------------------

Angelica joined my laboratory as part of a South Texas Advanced Research Training (START-UP) program at UTHSCSA. The goal of her project was to characterize the regional and temporal progression of A β and tau pathology in the 3xTg-AD mice.

Amanda Riojas	UTHSCSA	06/2011 - 07/2011
---------------	---------	-------------------

Amanda joined my laboratory for a summer internship as part of the Physiology Undergraduate Research Experience. The goal of her project was to elucidate the molecular basis underlying the gender difference in A β pathology in a mouse model of Alzheimer's disease.

Asta Vasalauskaite	UTHSCSA	08/2010 – 08/2011
--------------------	---------	-------------------

Asta was a participant in the Ulster Undergraduate Research Program, a partnership between the Department of Physiology and The University of Ulster, Coleraine to provide Ulster second-year undergraduate students with a research internship at UTHSCSA as part of their B.Sc. Honors degree in Biomedical Science. During her time in my laboratory, Asta learned how to perform PCR and Western blot experiments and participated in a project focused on elucidating the role of mTOR in the pathogenesis of Alzheimer's disease.

Andrea Magri	UTHSCSA	01/2010 - 01/2011
--------------	---------	-------------------

Andrea was a visiting undergraduate student from Italy, who spent one year in my laboratory. The goal of his project was to determine the role of mTOR in the tau-mediated neurodegeneration. Currently, Andrea is postdoctoral fellow at the University of Catania, Italy.

Fiona Thornton	UTHSCSA	11/2008 - 08/2009
----------------	---------	-------------------

Fiona was a participant in the Ulster Undergraduate Research Program, a partnership between the Department of Physiology and The University of Ulster, Coleraine to provide Ulster second-year undergraduate students with a research internship at UTHSCSA as part of their B.Sc. Honors degree in Biomedical Science. During her time in my laboratory, Fiona learned how to perform PCR, immunohistochemistry and Western blot experiments and participated in a project focused on elucidating the role of rapamycin in the pathogenesis of Alzheimer's disease.

High School Students Supervision

Student	Institution	Date
Nikhil Dave	Arizona State University	05/2015 – 07/2018

Nik is a Horizon Honors High School Student who joined my laboratory in 2015 as a volunteer. He has contributed to several projects in the laboratory. Currently, he is a senior in high school and has already been accepted into multiple universities. **He also was recently awarded the Flinn Scholarship.**

RESEARCH

Current Research Grants

Project #: R01AG061134

Funding Agency: NIH – National Institute on Aging

Title: RIPK1 as a novel kinase involved in the pathogenesis of Alzheimer’s disease

Period: 03/2019 - 02/2024

Role: Principal Investigator

Grant Detail: The goal of this grant is to dissect the role of this protein kinase in Alzheimer’s disease.

Project #: R01AG063454

Funding Agency: NIH – National Institute on Aging

Title: mTOR at the crossroad between aging and Alzheimer’s disease

Period: 04/2019 - 02/2024

Role: Principal Investigator

Grant Detail: The goal of this grant is to dissect the mechanisms by which aging contributes to Alzheimer’s disease.

Project #: 1R01AG057596-01A1

Funding Agency: NIH – National Institute on Aging

Title: Necroptosis as a novel mechanism of neurodegeneration in Alzheimer’s disease

Period: 09/2018 - 05/2023

Role: Principal investigator

Grant detail: The overall goal of this grant is to study the mechanisms of neuronal loss in Alzheimer’s disease focusing on necroptosis, a programmed form of cell death.

Project #: 2R01AG037637-07

Funding Agency: NIH – National Institute on Aging

Title: Molecular interplay between A β , tau and mTOR: Mechanisms of neurodegeneration

Period: 08/2016 - 07/2021

Role: Principal Investigator

Grant Detail: The objective of this proposal is to elucidate the role of the mammalian target of rapamycin in the pathogenesis of Alzheimer’ disease.

Project #: N/A

Funding Agency: University of Arizona

Title: Brain Aging and Neurodegeneration

Period: 06/2017 - 05/2020

Role: Principal Investigator

Grant detail: This is a subaward from a postdoctoral training grant to study brain aging and neurodegenerative diseases.

COMPLETED RESEARCH GRANTS:

Project #: 1R21NS096375-01A1

Funding Agency: NIH – National Institute of Neurological Disorders and Stroke

Title: Tau conditional knockout mice to elucidate the function of tau in the adult brain

Period: 08/2016 - 07/2018 (no cost extension until 07/2019)

Role: Principal Investigator

Grant Detail: The objective of this proposal is to assess the role of tau in the adult brain

Project #: N/A

Funding Agency: Sentinel Oncology

Title: Determine the effects of FS115 and SOL784 on the AD-like pathology in 3xTg-AD mice

Period: 12/2017 - 01/2019

Role: Principal investigator

Grant detail: To determine whether pharmacological inhibition of the ribosomal protein S6 kinase 1 (S6K1) with FS-115 and SOL784 is a valid approach to prevent or slow down the progression of Alzheimer's disease (AD)-like pathology in 3xTg-AD mice.

Project #: N/A

Funding Agency: Arizona Alzheimer's Consortium

Title: A novel mouse model to study neurodegeneration in Alzheimer's disease

Period: 07/2018 - 06/2019

Role: Principal investigator

Grant detail: The main objective of this grant is to develop a new mouse model to study the role of RIPK1 in Alzheimer's disease.

Project #: AARG-17-503765

Funding Agency: Alzheimer's Association

Title: Molecular mechanisms of cognitive decline in Alzheimer's disease

Period: 01/2017-01/2020

Role: Mentor (PI: Antonella Caccamo, Assistant Research Professor in my lab)

Grant Detail: The overall objective of this proposal is to elucidate the role NR4A2 on AD pathogenesis.

Project #: N/A

Funding Agency: Alzheimer's Association

Title: Pim1 inhibition as a therapeutic strategy for Alzheimer's disease

Period: 10/2016 - 09/2019

Role: Mentor (PI: Ramon Velazquez, a postdoctoral fellow in my laboratory)

Grant detail: The main objective of this grant is to perform preclinical studies to test a selective Pim1 inhibitor on AD-like pathology in mice.

Project #: 20150804

Funding Agency: Alzheimer's Drug Discovery Foundation

Title: Testing of selective DYRK1A inhibitors as a novel treatment of AD

Period: 04/2016 - 10/2018

Role: Collaborator (PI: Travis Dunckley)

Grant detail: The goal is to test the therapeutic potential of DYR219 and DYR266, two novel DYRK1A antagonists that we have generated, toward the prevention of cognitive impairment and Alzheimer's disease pathology using the 3xTg-AD mouse model.

Project #: 1606833

Funding Agency: National Science Foundation

Title: Elucidating the molecular mechanisms linking maternal choline supplementation to healthy cognitive aging

Period: 08/2016 - 07/2018

Role: Mentor (PI: Ramon Velazquez, a postdoctoral fellow in my laboratory)

Grant detail: The main objective of this grant is to assess the role of choline administration on cognitive aging.

Project #: N/A

Funding Agency: Arizona Alzheimer's Consortium

Title: Determine the role of necroptosis in Down syndrome

Period: 07/2017 - 06/2018

Role: Mentor (PI: Antonella Caccamo, Assistant Research Professor in my lab)

Grant detail: The main objective of this grant is to study the mechanisms of neurodegeneration in Down syndrome.

Project #: N/A

Funding Agency: Arizona Alzheimer's Consortium

Title: Novel mechanisms of neuronal death in Alzheimer's disease

Period: 07/2017 - 06/2018

Role: Mentor (PI: Caterina Branca, a postdoctoral fellow in my lab)

Grant detail: The objective of this grant is to assess the role of RIPK1 in Alzheimer's disease

Project #: N/A

Funding Agency: Arizona Alzheimer's Consortium

Title: Staging the progression of AD-like pathology in 3xTg-AD mice

Period: 07/2017 - 06/2018

Role: Principal investigator

Grant detail: The main objective of this grant is to characterize the progression of neuropathology and behavioral alterations in 3xTg-AD mice.

Project #: N/A

Funding Agency: Arizona Alzheimer's Consortium

Title: Assessing the role of necroptosis in Alzheimer's disease

Period: 07/2016 - 06/2017

Role: Principal investigator

Project #: N/A

Funding Agency: Arizona Alzheimer's Consortium

Title: Dissecting the role of tau in the adult mouse brain

Period: 07/2015 - 06/2016

Role: Principal investigator

Project #: 1R01AG037637-01

Funding Agency: NIH – National Institute on Aging

Title: Molecular interplay between A β , tau and mTOR: Mechanisms of neurodegeneration

Period: 08/2011 - 07/2016

Role: Principal Investigator

Project #: N/A

Funding Agency: NIH - National Institute on Aging

Title: Mechanism of Amyloid-beta mediated mTOR dysregulation in neurodegeneration

Period: 05/2013 - 08/2015

Role: Mentor (PI: Elena Wisely, at the time of the award she was a Ph.D. candidate)

Project #: N/A

Funding Agency: Alzheimer's Drug Discovery Foundation

Title: Reducing mTOR activity as a treatment for Alzheimer's disease

Period: 08/2013 - 07/2015 (no cost extension until 03/2016)

Role: Principal Investigator

Project #: N/A

Funding Agency: Barrow Neurological Institute and Department of Basic Medical Sciences COM-Phoenix

Title: PACAP deficit and the pathogenesis of Alzheimer's disease

Period: 07/2014 - 06/2015

Role: Co-Principal Investigator

Project #: N/A

Funding Agency: Arizona Alzheimer's Consortium

Title: Establishing a transgenic mouse core for the Arizona Alzheimer's Consortium

Period: 07/2014 - 06/2015

Role: Principal investigator

Project #: N/A

Funding Agency: Arizona Alzheimer's Consortium

Title: Elucidating the role of p62 in Alzheimer's disease pathogenesis

Period: 07/2014 - 06/2015

Role: Co-Principal Investigator

Project #: N/A

Funding Agency: Arizona Alzheimer's Consortium

Title: Cognitive decline associated with enduring inflammation in the wake of traumatic brain injury over the rodent lifespan

Period: 07/2014 - 06/2015

Role: Co-Principal Investigator

Project #: N/A

Project #: **NRSA award**

Funding Agency: NIH - National Institute on Aging

Title: Molecular mechanisms underlying Frontotemporal Lobar Degeneration

Period: 07/2012 - 06/2014

Role: Mentor (PI: David Medina, at the time of the award he was a Ph.D. student)

Project #: N/A

Funding Agency: Charleston Conference on Alzheimer's Disease

Title: Restoring cognition by remotely stimulating selective neuronal networks.

Period: 07/2013 - 06/2014
Role: Principal Investigator

Project #: 2010 OWENS FDN
Funding Agency: The William and Ella Owens Medical Research Foundation
Title: Molecular interplay between Abeta, tau and mTOR: Mechanisms of neurodegeneration
Period: 03/2011 - 06/2013
Role: Principal Investigator

Project #: N/A
Funding Agency: Glenn Foundation
Title: Biological mechanisms of aging
Period: 08/2011 - 07/2013
Role: Principal Investigator

Project #: 2011
Funding Agency: American Federation for Aging Research
Title: β 2 adrenergic receptors as mediators of the A β -induced cognitive decline.
Period: 07/2011 - 06/2013
Role: Principal Investigator

Project #: NIRG-10-173571
Funding Agency: Alzheimer's Association
Title: The role of chaperone-mediated autophagy in Alzheimer's disease
Period: 10/2010 - 09/2012
Role: Principal Investigator

Project #: RC2AG036613
Funding Agency: NIH - National Institute on Aging
Title: Can Rapamycin Retard Age-Related Diseases?
Period: 10/2009 - 09/2011 (No-cost extension until 09/2012).
Role: Co-Principal Investigator for Project 2

Project #: K99/R00 AG-02972
Funding Agency: NIH - National Institute on Aging
Title: Molecular Mechanisms of Memory Loss in a Transgenic Model of Alzheimer's Disease
Period: 07/2007 - 02/2012
Role: Principal Investigator

Project #: AG013319
Funding Agency: Nathan Shock Center
Title: Elucidating the role of TDP-43 in disease pathogenesis
Period: 07/2010 - 06/2011
Role: Principal Investigator

Project #: N/A
Funding Agency: University of Texas Health Science Center at San Antonio, University Research Council Grants Program Award

Title: Modeling Frontotemporal Lobar Degeneration in Mice.
Period: 04/2009 - 03/2010
Role: Principal Investigator

INVITED PRESENTATIONS AT MEETINGS, ACADEMIC INSTITUTIONS AND PHARMACEUTICAL COMPANIES:

- Nrf2 at the crossroad between aging and Alzheimer's disease. Experimental Biology meeting, Orlando, FL. **Details:** *Invited by Karyn Hamilton, Ph.D.* 04/2019
- mTOR and necroptosis in Alzheimer's disease: Partners in crime. Department of Medical and Molecular Genetics, Indiana University School of Medicine. Indianapolis, IN. **Details:** *Invited by Bruce Lamb, Ph.D.* 02/2019
- mTOR and necroptosis in Alzheimer's disease: Partners in crime. University of Southern California, Los Angeles, CA. **Details:** *Invited by Jeff Chen, Ph.D.* 02/2019
- mTOR and necroptosis in Alzheimer's disease: Partners in crime. Department of Neuroscience and Regenerative Medicine, Medical College of Georgia, Augusta University, Augusta, GA. **Details:** *Invited by Xinyun Li, Ph.D.* 02/2019
- Necroptosis activation in Alzheimer's disease. Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, PA. **Details:** *Invited by Peter Baas, Ph.D.* 11/2018
- mTOR/S6K1 at the crossroad between aging and Alzheimer's disease. Regional Healthy Aging and Dementia Research Symposium. Lubbock, TX. **Details:** *Invited by Hemachandra Reddy, Ph.D.* 10/2018
- Aging and neurodegeneration: The mTOR connection. The 2018 Nathan Shock Centers Bi-Annual Directors' Symposium. Philadelphia, PA. **Details:** *Invited by Mrs. Odette van der Willik* 06/2018
- mTOR and necroptosis in Alzheimer's disease: Partners in crime. Aging and Brain Symposium, San Antonio, TX. **Details:** *Invited by Miranda Orr, Ph.D.* 05/2018
- Dissecting the role of mTOR and necroptosis in Alzheimer's disease. Neurology Grand Rounds, University of Arizona, Tucson, AZ. **Details:** *Invited by Anita Koshy, Ph.D.* 01/2018
- Dissecting the role of mTOR and necroptosis in Alzheimer's disease. Department of Basic Medical Sciences, University of Arizona, College of Medicine-Phoenix, Phoenix, AZ. **Details:** *Invited by Ronald Hammer, Ph.D.* 01/2018
- Necroptosis activation in Alzheimer's disease. Regulated Necrosis: Pathways and Mechanisms Meeting, The Banbury Center at Cold Spring Harbor Laboratory. Lloyd Harbor, NY. **Details:** *Invited by Douglas Green, Ph.D.* 11/2017

<u>Dissecting the role of mTOR and necroptosis in neurodegeneration.</u> Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University. New York, NY. Details: <i>Invited by Ottavio Arancio, Ph.D.</i>	10/2017
<u>Dissecting the role of mTOR and necroptosis in neurodegeneration.</u> University of Oklahoma Health Science Center. Oklahoma City, OK. Details: <i>Invited by Arlan Richardson, Ph.D.</i>	10/2017
<u>Dissecting the role of mTOR and necroptosis in neurodegeneration.</u> Denali Therapeutics, San Francisco, CA. Details: <i>Invited by Jonas Hannestad, Ph.D.</i>	08/2017
<u>Dissecting the role of mTOR and necroptosis in neurodegeneration: Therapeutic implications for Alzheimer's disease.</u> Roche Pharmaceutical, Basel, Switzerland. Details: <i>Invited by Kelly Bales, Ph.D.</i>	04/2017
<u>mTOR at the crossroad between aging and Alzheimer's disease.</u> University of Arizona, Graduate Interdisciplinary program. Tucson, AZ. Details: <i>Invited by Daniela Zarnescu, Ph.D.</i>	09/2016
<u>Mechanisms of Neurodegeneration in Alzheimer's disease.</u> Department of Biomedical and Biotechnological Sciences. University of Catania, Italy. Details: <i>Invited by Vito De Pinto, Ph.D.</i>	07/2016
<u>Alzheimer's disease and aging: The mTOR connection.</u> New York State Institute for Basic Research. Staten Island, NY. Details: <i>Invited by Cheng-Xin Gong, M.D.</i>	03/2016
<u>The mammalian target of rapamycin at the crossroad between Alzheimer's disease and diabetes.</u> The 11 th International Symposium on Geriatrics and Gerontology, Morioka, Obu, Aichi, Japan. Details: <i>Invited by Katsuhiko Yanagisawa, M.D.</i>	02/2016
<u>The mammalian target of rapamycin at the crossroad between aging and Alzheimer's disease.</u> Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston TX. Details: <i>Invited by Anson Pierce, Ph.D.</i>	11/2015
<u>mTOR signaling links Aβ and tau to cognitive decline: Evidence from animal models.</u> School of Life Sciences, Arizona State University, Tempe, AZ. Details: <i>Invited by Jeanne Wilson-Rawls, Ph.D.</i>	09/2015
<u>mTOR signaling links Aβ and tau to cognitive decline: Evidence from animal models.</u> The Biodesign Institute at Arizona State University, Arizona State University, Tempe, AZ. Details: <i>Invited by Marco Mangone, Ph.D.</i>	09/2015
<u>Molecular Interplay Among mTOR, Aβ and tau: Therapeutic Implications for Alzheimer's Disease.</u> Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, Irvine, CA. Details: <i>Invited by Kim Green, Ph.D.</i>	04/2015
<u>Chemogenetic tools to remotely stimulate neuronal networks in Alzheimer's disease.</u> Charleston Conference on Alzheimer's disease, Charleston, SC. Details: <i>Invited by Joseph Helpert, Ph.D.</i>	02/2015

- mTOR plays a key role in AD pathogenesis. Barrow Neurological Institute Neuroscience Conference, Phoenix, AZ. **Details:** *Invited by Pengcheng Han, Ph.D.* 08/2014
- Dissecting the role of mTOR in Alzheimer's disease. Department of Neuroscience, Rosalind Franklin University, Chicago, IL. **Details:** *Invited by Beth Stutzmann, Ph.D.* 04/2014
- mTOR signaling links A β and tau to cognitive decline: Evidence from animal models. Department of Psychology, Arizona State University, Tempe, AZ. **Details:** *Invited by Federico Sanabria, Ph.D.* 03/2014
- mTOR signaling links A β and tau to cognitive decline: Evidence from animal models. Department of Basic Medical Sciences, University of Arizona, College of Medicine-Phoenix, Phoenix, AZ. **Details:** *Invited by Aparna Sertil, Ph.D.* 01/2014
- mTOR signaling links A β and tau to cognitive decline: Evidence from animal models. Department of Biology, University of Virginia, Charlottesville, VA. **Details:** *Invited by George Bloom, Ph.D.* 12/2013
- Dissecting the role of mTOR in Alzheimer's disease. Center for Dementia Research, Nathan S. Kline Institute, Orangeburg, NY. **Details:** *Invited by Masuo Ohno, Ph.D.* 10/2013
- Molecular Interplay Among mTOR, A β and tau: Therapeutic Implications for Alzheimer's Disease. 7th Neurodegenerative Conditions Research and Development, Boston, MA (Invited Speaker). 09/2013
- Glucocorticoids exacerbate cognitive deficits in TDP-25 transgenic mice via a glutathione-mediated mechanism: implications for aging, stress and TDP-43 proteinopathies. American Aging Association 42nd Annual Meeting, Baltimore, MD (Invited Speaker). 06/2013
- Rapamycin as a Potential Therapeutic for Alzheimer's Disease. Translating Natural Products into Drugs for Alzheimer's and Neurodegenerative Disease. The New York Academy of Sciences, New York (Invited Speaker). 05/2013
- Molecular interplay among A β , tau and mTOR: Therapeutic implications for Alzheimer's disease. Dip. di Scienze Biologiche, Geologiche e Ambientali, University of Catania, Italy. **Details:** *Invited by Vito De Pinto, Ph.D.* 12/2012
- Molecular interplay among A β , tau and mTOR: Therapeutic implications for Alzheimer's disease. Department of Biochemistry & Molecular Biology, University of Maryland School of Medicine, Baltimore, MD. **Details:** *Invited by Danna Zimmer, Ph.D.* 11/2012
- Molecular interplay among A β , tau and mTOR: Therapeutic implications for Alzheimer's disease. Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA. **Details:** *Invited by Xiao-Feng Yang, M.D., Ph.D.* 11/2012
- Molecular interplay among A β , tau and mTOR in Alzheimer's disease: Therapeutic implications. Department of Biochemistry, University of Texas Health Science Center at San Antonio, TX. **Details:** *Invited by Bruce Nicholson, Ph.D.* 10/2012

- The Role of mTOR Signaling in Alzheimer's Diseases: Therapeutic Implications. 6th Neurodegenerative Conditions Research and Development, San Francisco, CA (Invited Speaker). 09/2012
- The role of mTOR in Alzheimer's disease. Psychiatry and Neuroscience Center, French National Institute of Health and Medical Research (Inserm). *Details: Invited by Christian Neri, Ph.D.* 09/2012
- Molecular interplay among A β , tau and mTOR in Alzheimer's disease. The Barshop Institute for Longevity and Aging Studies, San Antonio, TX. *Details: Invited by Carlos Orihuela, Ph.D. and Jim Nelson, Ph.D.* 08/2012
- The role of mTOR in Alzheimer's disease: Lessons from animal models. Banner Sun Health Research Institute, Phoenix, AZ. *Details: Invited by Eric Reiman, M.D.* 05/2012
- The role of mTOR in Alzheimer's disease: Lessons from animal models. 43th Annual American Society for Neurochemistry meeting. Baltimore, MD (Invited speaker). 05/2012
- The role of mTOR in Alzheimer's disease. Department of Neuroscience, Mayo Clinic Florida. Jacksonville, FL. *Details: Invited by Malcolm Leissring, Ph.D.* 10/2011
- Molecular interplay between A β , tau and mTOR: Mechanisms of neurodegeneration. 5th Neurodegenerative Conditions Research and Development, San Francisco, CA (Invited Speaker). 09/2011
- Molecular interplay between A β , tau and mTOR: Mechanisms of neurodegeneration. Lilly UK, Windlesham, UK. *Details: Invited by Mike Hutton, Ph.D.* 06/2011
- Molecular interplay between Abeta, tau and mTOR: Mechanisms of neurodegeneration. The International Conference on Alzheimer's Disease, Honolulu, HI (Invited Speaker). 07/2010
- The role of mTOR in neurodegeneration. Aging and TOR Signaling meeting, Ann Arbor, MI. *Details: Invited by Susan V. Brooks, Ph.D.* 05/2010
- The role of mTOR in neurodegeneration. Texas A&M University, College Station, TX. *Details: Invited by Danna Zimmer, Ph.D.* 05/2010
- Molecular interplay between Abeta, tau and mTOR: Mechanisms of neurodegeneration. University of Southern California, Los Angeles, CA. *Details: Invited by Christian Pike, Ph.D.* 03/2010
- Molecular Mechanisms of Memory Loss in a Transgenic Model of Alzheimer's Disease. University of Texas Health Science Center, San Antonio, Department of Cellular and Structural Biology, San Antonio, TX. *Details: Invited by Yidong Bai, Ph.D.* 05/2009
- The effect of anti-Abeta interventions on tau pathology and cognitive decline. Experimental Biology Meeting, Experimental Biology Meeting, New Orleans, LA (Invited Speaker) 04/2009
- Abeta accumulation facilitates the onset and progression of tau pathology in a transgenic model of Alzheimer's disease. University of Texas Health Science Center, San Antonio, 04/2009

Department of Pharmacology, San Antonio, TX. **Details:** *Invited by Lance R. McMahon, Ph.D.*

Abeta and Tau Interaction in a transgenic model of Alzheimer's disease. Brain Diseases and molecular machines, Paris, France. **Details:** *Invited by Christian Neri, Ph.D.* 03/2008

Abeta and Tau Interaction in a transgenic model of Alzheimer's disease. Servier Research Institute, Paris, France. **Details:** *Invited by Antoine Bril, Ph.D.* 03/2008

Abeta and Tau Interaction in a transgenic model of Alzheimer's disease. University of Catania, Italy. **Details:** *Invited by Agata Copani, Ph.D.* 03/2008

Abeta and Tau Interaction in a transgenic model of Alzheimer's disease. University of Texas, Health Science Center San Antonio, Department of Physiology, San Antonio, TX. **Details:** *Invited by David Weiss, Ph.D.* 01/2008

Abeta and Tau Interaction in a transgenic model of Alzheimer's disease. University of North Carolina, NC. **Details:** *Invited by William Snider, Ph.D.* 01/2008

Abeta and Tau Interactions. Texas A&M, Health Science Center, College Station, TX. **Details:** *Invited by William H. Griffith, Ph.D.* 11/2007

Abeta and Tau Interactions. University of Kentucky, Lexington, KY. **Details:** *Invited by William R. Markesbery, M.D.* 10/2007

Abeta and Tau Interactions. University of South Florida, Tampa, FL. **Details:** *Invited by Marcia Gordon, PhD and Huntington Potter, Ph.D.* 10/2007

Abeta immunotherapy in Alzheimer disease. The 9th Argentinian Congress of Neuropsychiatry, Argentina (Invited Speaker). **Details:** *Unable to attend.* 09/2007

Abeta and Tau Interactions in a Novel Transgenic Model of Alzheimer's Disease. The Jackson Laboratory, Discovery Strategies Conference, Bar Harbor, ME (Invited Speaker). 06/2007

Abeta and Tau Interactions in a Novel Transgenic Model of Alzheimer's Disease. Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland. **Details:** *Invited by Patrick Aebischer, MD.* 05/2007

Abeta and Tau Interactions in a Novel Transgenic Model of Alzheimer's Disease. University of California, Los Angeles, CA. **Details:** *Invited by John Ringman, MD.* 05/2007

Studying and Treating AD in Mice. 6th Annual Meeting of the Society for Experimental Pharmacology and Therapeutics, San Diego, CA (Invited Speaker). 10/2006

M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice. 2006 Alzheimer's Disease Research Conference, Caregiver Stress, Inflammation, and Treatment Options, Irvine, CA (Invited Speaker). 10/2006

<u>Abeta and Tau Interactions in a Novel Transgenic Model of Alzheimer's Disease.</u> Boehringer Ingelheim, GM. <i>Details: Invited by Cornelia Dorner-Ciossek, Ph.D.</i>	04/2006
<u>Studying and Treating Alzheimer's Disease in Mice.</u> 37th Annual Meeting, American Society for Neurochemistry, Portland, OR (Invited Speaker)	03/2006
<u>Studying and Treating Alzheimer's Disease in Mice.</u> University of Dartmouth, Dartmouth, MA. <i>Details: Invited by TY Chang, Ph.D.</i>	08/2005
<u>Studying and Treating Alzheimer's Disease in Mice.</u> Alzheimer's disease research center. Institute for Aging and Dementia, University of California, Irvine, Irvine, CA. <i>Details: Invited by Carl Cotman, Ph.D.</i>	11/2004
<u>Abeta Immunotherapy and its Effect on Tau Pathology.</u> Elan pharmaceutical, San Francisco, CA. <i>Details: Invited by Manuel Buttini, Ph.D.</i>	08/2004
<u>Abeta and Tau Interaction in a Transgenic Model of Alzheimer's Disease.</u> Alzheimer's disease research center. Institute for aging and dementia, University of California, Irvine, Irvine, CA. <i>Details: Invited by Elizabeth Head, Ph.D.</i>	01/2004
ORAL PRESENTATIONS AT MEETINGS:	
<u>Necroptosis activation in Alzheimer's disease.</u> Advances in Alzheimer's and Parkinson's Therapies, Torino, Italy.	03/2018
<u>Mechanisms of Neuronal Loss in Alzheimer's Disease.</u> The 13th International Conference on Alzheimer's and Parkinson's diseases, Vienna, Austria.	04/2017
<u>mTOR/S6K1 at the crossroad between aging and Alzheimer's disease.</u> Neurodegenerative Diseases: Biology & Therapeutics, Cold Spring Harbor Laboratories. Cold Spring Harbor, NY	12/2016
<u>Reducing ribosomal protein S6 kinase 1 ameliorates Alzheimer's disease-like cognitive and synaptic deficits by reducing BACE-1 translation.</u> Alzheimer's Association International Conference, Washington, DC.	07/2015
<u>The mTOR/S6K1 pathway plays a key role in the pathogenesis of Alzheimer's disease.</u> The 12th International Conference on Alzheimer's and Parkinson's diseases, Nice, France.	03/2015
<u>Genetic reduction of mTOR signaling ameliorates Alzheimer's disease-related cognitive deficits and amyloid-β pathology by restoring hippocampal gene expression signature.</u> Alzheimer's Association International Conference, Copenhagen, Denmark.	07/2014
<u>The relationship among mTOR, Aβ and tau: Therapeutic implications for Alzheimer's disease.</u> Alzheimer's Association International Conference, Boston, MA.	07/2013
<u>The role of mTOR in Alzheimer's disease: Lessons from animal models.</u> Society for Neuroscience. New Orleans, LA.	10/2012

The role of mTOR in Alzheimer's disease: Lessons from transgenic mice. Alzheimer's Association International Conference. Vancouver, British Columbia, Canada. 07/2012

Age-dependent cognitive decline typical of FTL D in transgenic mice expressing the 25-kDa C-terminal fragment of TDP-43. Society for Neuroscience Conference, Washington, DC. 11/2011

Molecular interplay between A β , tau and mTOR: Mechanisms of neurodegeneration. The 10th international conference on Alzheimer's and Parkinson's diseases, Barcelona, Spain. 03/2011

Rapamycin improves learning and memory in a transgenic model of Alzheimer's disease. Society for Neuroscience Conference, Society for Neuroscience, Chicago, IL. 10/2009

Blocking Abeta42 accumulation delays the onset and progression of Tau pathology and cognitive decline via CHIP: A mechanistic link between Abeta and Tau pathology. The 11th international conference on Alzheimer's disease and related disorders, Chicago, IL. 07/2008

Modulation of the Cholinergic System in the 3xTg-AD Mice. The 10th Annual Alzheimer's Disease Conference, Boston, MA. 05/2008

Reduction of Both Soluble Abeta and Tau, but not Soluble Abeta Alone, Ameliorates Cognitive Decline in Transgenic Mice with Plaques and Tangles. Society for Neuroscience, San Diego, CA. 11/2007

Reduction of Both Soluble Abeta and Tau, but not Soluble Abeta Alone, Ameliorates Cognitive Decline in Transgenic Mice with Plaques and Tangles. The 10th international conference on Alzheimer's disease and related disorders, Madrid, Spain. 07/2006

Abeta Oligomers Precede Extracellular Plaque Formation in a Transgenic Model of Alzheimer's Disease. Society for Neuroscience, San Diego, CA. 11/2005

Chronic Nicotine Administration Exacerbates Tau Pathology in a Transgenic Model of Alzheimer's disease. 7th International Conference AD/PD 2005, Sorrento, Italy. 03/2005

PROFESSIONAL ARTICLES ABOUT MY PUBLISHED WORK:

Nature Medicine 12, 762 (2006). A transgenic triple scores a home run. 12/2006

Nature Medicine 11, 259 (2005). Smoking out Alzheimer's disease. 11/2005

Science 305, 762 (2004). Untangling Alzheimer's by pairing plaques bolsters amyloid theory. 06/2004

Science News 166, 83 (2004). Stopping Alzheimer's: antibody thwarts disease in mice. 06/2004

Neuron 43, 293-299 (2004). Clearing tau pathology with Abeta immunotherapy - reversible and irreversible stages revealed. 05/2004

Nature Reviews Neuroscience 5, 259 (2004). Hyperexcitability induces ataxia.	05/2004
Lancet (Neurology) 3, 576 (2004). Mouse model provides support for the amyloid cascade hypothesis.	03/2004
Nature Reviews Neuroscience 4, 701 (2003). Mighty Mouse.	04/2003

PATENTS:

Necroptosis Signaling as a Therapeutic Target for Alzheimer’s disease. Provisional Application No. 62356983.	07/2016
Treatment of neurodegenerative disease with CREB-binding protein. Provisional Application No. 61/568,458, Co-Inventor: Antonella Caccamo	12/2011
Inhibition of Mammalian Target of Rapamycin. Patent No. 13/128,800, Co-Inventor(s): Zelton Dave Sharp, John R. Strong, Veronica Galvan, Herbert G. Wheeler	11/2009

SERVICE

Service to Arizona State University

Description	Role	Dates
SOLS Graduate Program Committee	Committee Member	08/2017 – 06/2019
CLAS Graduate Committee	Committee Member	08/2017 – 06/2019
Interdisciplinary Graduate Program in Neuroscience	Director	07/2017 – 06/2019
Arizona Wellbeing Commons, Starring committee	Committee Member	01/2017 – 06/2019
Arizona Wellbeing Commons, Neuroscience division	Director	01/2017 – 06/2019
Biodesign Institute Personnel Committee	Committee Member	05/2016 – 06/2019
Poster Session –Biodesign Scientific Retreat	Committee Chair	01/2017 – 04/2017
Molecular and Cellular Biology Graduate Program– Executive Committee	Committee Member	12/2016 – 07/2017
Neuroscience Committee to create a Neuroscience Major	Committee Member	02/2016 – 05/2017
Interdisciplinary Graduate Program in Neuroscience –Executive	Committee Member	09/2015 – 06/2017

Service to the Banner Sun Health Research Institute

Description	Role	Dates
IACUC Committee	Committee Member	11/2013 – 07/2015

Service to the University of Arizona, College of Medicine-Phoenix

Description	Role	Dates
Curricular Evaluation work group for the Neuromusculoskeletal Block	Committee Member	03/2014 – 07/2015

Early Stage Investigator Committee	Committee Member	09/2013 – 07/2015
------------------------------------	------------------	-------------------

Service to the University of Texas Health Science Center at San Antonio

Description	Role	Dates
Fundamentals of Biomedical Science Review Committee.	Committee Member	03/2013– 06/2013

The objective of this committee is to modify the INTD5000 core course based on students and faculty feedback from the previous year.

Faculty Search Committee.	Committee Member	12/2012-06/2013
---------------------------	------------------	-----------------

The objective of this committee is to recruit a new Faculty member for the Department of Physiology.

Committee on Graduate Studies for the MCIP track.	Committee Member	09/2011-06/2013
---	------------------	-----------------

The Molecular, Cellular and Integrative Physiology COGS is responsible for monitoring students' academic progress in educational and research activities, attesting eligibility for admission to Ph.D. candidacy.

Library Committee.	Committee Member	08/2011-06/2013
--------------------	------------------	-----------------

The committee serves in consultative and advisory capacity to the President and Vice President for Academic Administration and to work with and assist the Director of the Library in making recommendations for Library practices and procedures. To review and advise on the development of priorities in areas that have an impact on academic efficiency and effectiveness to ensure that the services provided by the Library reflect the needs and interests of the academic community.

Department of Physiology Faculty Compensation (XYZ) Plan Committee.	Committee Member	09/2012-12/2012
---	------------------	-----------------

The task of the committee is to undertake candid, unbiased and constructive deliberations, keeping in view the high standards that we expect of our faculty, to create a reward mechanism for the Physiology faculty and thus help ensure the future success of the Department of Physiology.

Department of Physiology: Task Force Committee	Committee Member	09/2012-12/2012
--	------------------	-----------------

The principal charges of this committee are: (i) Faculty Recruitment; (ii) Invigorating interactions among existing faculty; (iii) Invigorating interactions among students.

Recruitment Coordinator for MCIP Track (School level).	Committee Member	09/2011-07/2012
--	------------------	-----------------

The primary role of the committee is to refine, prioritize and execute the findings of the School Recruitment Committee. The committee organizes the recruitment weekends for the IMGP applicants

Recruitment Coordinator for MCIP Track (Track Committee Member level) Chair. 09/2011-07/2012

This committee will develop strategies to help to increase the quality of students applying to the IMG P program and enrolling into the MCIP track.

Barshop Advisory Committee for Biomedical Research Committee Member. 04/2011-06/2012

The committee discusses the progress of the Barshop Institute concerning current programs in aging and future directions. It plays an essential function in gaining input from across the research community concerning research and training programs in basic biomedical research in aging.

South Texas Research Facility Neuroscience Committee Member 03/2011-03/2012
Committee Member Director Search Committee.

The objective of this committee is to recruit a Director for the Neuroscience area of the South Texas Research Facility.

Graduate Student Task Force Committee Committee Member 02/2010-01/2011

IMG P admission and distribution committee member. Committee Member 09/2009-09/2010

The goal of this committee is to review students' application for the IMG P program and make recommendations to the Dean's office as to the students that should be accepted. The committee members also serve as mentors for first-year graduate students in the IMG P program.

Organizing the Barshop Seminar Series. Committee Member 09/2009-05/2012

The objective of this committee is to coordinate and oversee the Barshop seminar series, a weekly event throughout the academic year.

Faculty Search Committee Committee Member 07/2009-02/2010

The objective of this committee is to recruit a new Faculty member for the Department of Physiology.

Postdoctoral travel award selection committee Committee Member 01/2009-06/2013

Presenting at the Postdoctoral seminar series Presenter 11/2008-11/2008

Service to the profession

Description	Role	Dates
<i>Aging Cell</i>	Supervising Editor	12/2016 – Present
Arizona Alzheimer's Consortium Internal Scientific Advisory Committee	Committee Member	05/2016 – Present
<i>Brain Research</i>	Senior Editor	04/2016 – Present
<i>Neuroscience Journal</i>	Editorial Board Member	07/2012 - 2/2013
<i>Frontiers in Psychiatry</i>	Review Editor	01/2010 –12/2013
Journal Review Service	Ad Hoc Reviewer	01/2006-Present

Science, Nature Reviews Neuroscience, Neurobiology of Aging, The FASEB Journal, Journal of Neuroscience, Proceedings of the National Academy of Science, Aging Cell, Journal of Neuroscience Methods, Frontiers in Bioscience, Journal of Alzheimer's disease, NeuroMolecular Medicine, Journal of Neuroinflammation, Cell Death and Differentiation, Journal of Cellular and Molecular Medicine, Journal of Neurochemistry, PloSONE, Brain Research, Journal of Comparative Neurology, Current Alzheimer's Research, European Journal of Neuroscience, Molecular Neurodegeneration, Current Enzyme Inhibition. Future Neurology, Acta Neuropathologica, Biological Psychiatry, Neurochemistry International, Molecular Psychiatry, American Journal of Pathology, Nature Communications, Nature Neuroscience.

Reviewer for Granting Agencies

Granting Agency	Role	Dates
NIH Cellular and Molecular Biology of Neurodegeneration Study Section	Permanent Member	07/2018 – Present
Alzheimer's Drug Discovery Foundation	Permanent Member	10/2011 - Present
Alzheimer's Association (USA)	Ad Hoc Reviewer	04/2008 - Present
NIH Neurological Sciences and Disorders B	Ad Hoc Reviewer	10/2017
NIH Neural Oxidative Metabolism and Death Study Section	Ad Hoc Reviewer	10/2017
NIH Special Emphasis Panel/ ZRG1 MDCN-T(56)	Committee Member	06/2017
NIH Special Emphasis Panel/ ZRG1 MDCN-T(56)	Committee Member	11/2016
Darrel K Royal Research Fund for Alzheimer's disease	Ad Hoc Reviewer	09/2016
NIH Special Emphasis Panel/ ZRG1 MDCN-T(56)	Committee Member	06/2016
NIH Special Emphasis Panel/ ZRG1 MDCN-T(56)	Committee Member	03/2016
Texas Alzheimer's Research and Care Consortium	Ad Hoc Reviewer	07/2015
NIH Special Emphasis Panel/Scientific Review Group	Committee Member	04/2015
NIH Special Emphasis Panel for Alzheimer's Disease Research Center applications	Committee Member	10/2014
NIH Cellular and Molecular Biology of Neurodegeneration Study Section	Ad Hoc Reviewer	06/2014

NIH Cellular and Molecular Biology of Neurodegeneration Study Section	Ad Hoc Reviewer	02/2014
American Federation for Aging Research Review Panel	Committee Member	05/2013– 04/2014
NIH Chronic Dysfunction and Integrative Neurodegeneration study section	Ad Hoc Reviewer	06/2013
Alzheimer's Society (UK)	Ad Hoc Reviewer	01/2009 - 07/2013
Biotechnology and Biological Research Council Sciences (UK)	Ad Hoc Reviewer	07/2012
NIH Molecular Neurogenetics Study Section	Ad Hoc Reviewer	06/2012
NIH Human Cell Reprogramming for Aging and Alzheimer's Disease	Committee Member	03/2012
NIH Translational Research in Aging, ZAG1 ZIJ-1	Ad Hoc Reviewer	01/2012
NIH Special Emphasis Panel/Scientific Review Group	Ad Hoc Reviewer	09/2011
NIH Molecular Neurogenetics study section	Ad Hoc Reviewer	09/2011
US Department of Veterans Affairs RR&D	Ad Hoc Reviewer	08/2010
Dutch Internationale Stichting Alzheimer Onderzoek	Ad Hoc Reviewer	07/2010
Institute for Integration of Medicine and science clinical and translational science award	Ad Hoc Member	04/2010 - 07/2012
Israel Science Foundation	Reviewer	03/2009 - 04/2010
Medical Research Council, London (United Kingdom)	Reviewer	03/2009 - 04/2010
U.S.-Israel Binational Science Foundation	Reviewer	02/2009 - 03/2010
International Alzheimer's Research Foundation (Italy)	Reviewer	01/2005
Service to the Public		
Description	Role	Dates
SFN-sponsored Alzheimer's disease social, New Orleans, LA.	Committee Chair	10/2012
Brain Bowl 2010 directed by David Morilak, Ph.D.	Judge	03/2010

PROFESSIONAL ORGANIZATIONS

Society for Neuroscience (Membership)	01/2002–12/2015
New York Academy of Sciences (Membership)	04/2013– 03/2014

PROFESSIONAL DEVELOPMENT:

Description	Date
CV and Personal Statement Workshop. Arizona State University.	02/26/2018
Developing the New Generation of Researchers: Mentoring Graduate Students and Postdocs through the IDP workshop. Arizona State University.	04/18/2017
Peer Teaching Evaluation Workshop. Arizona State University.	09/30/2016
Case-Based Instruction (CBI) Curriculum Training at the University of Arizona, College of Medicine-Phoenix	09/25/2013
Academic Center for Excellence in Teaching, University of Texas Health Science Center at San Antonio. Teaching Skills Workshops – Reflection in action	04/24/2012
Academic Center for Excellence in Teaching, University of Texas Health Science Center at San Antonio. Teaching Skills Workshops – Unlearning in order to learn	04/10/2012
Academic Center for Excellence in Teaching, University of Texas Health Science Center at San Antonio. Teaching Skills Workshops - Critical Thinking	03/20/2012
NeuroStereology Workshop. The goal of the workshop is to teach a small group of research scientists how to design, supervise, and critically evaluate stereological studies of the nervous system.	11/10/2011
Case-Based Teaching Workshop. Presented by Jennifer Peel at University of Texas Health Science Center at San Antonio	02/18/2009
Promotion and Tenure Faculty, Workshop on promotion and tenure for tenure-track faculty at UTHSCSA.	02/04/2009

PUBLICATIONS:

PEER-REVIEWED ARTICLES

Google Scholar Citation Indexes: Total Citations: 24,332; **h-index 59:**

https://scholar.google.com/citations?hl=en&user=OXHDKSwAAAAJ&view_op=list_works&sortby=pubdate

Peer-Reviewed Research Articles (total 94)

The impact factors are reported for the year when the article was published and were obtained from the Journal home page. The number of citations were obtained from Google Scholar and last accessed on March 25, 2019.

1. Vartak RS, Rodin A, Oddo S. Differential activation of the mTOR/autophagy pathway predicts cognitive performance in APP/PS1 mice. *Neurobiol Aging. in press.*
**Journal impact factor: 5.153 Number of times cited: 0
2. Velazquez R, Ferreira E, Knowles S, Fux C, Rodin A, Winslow W, Oddo S. Lifelong choline supplementation ameliorates Alzheimer's disease pathology and associated cognitive deficits by attenuating microglia activation. *Aging Cell. 2019 Sep 27:e13037*
**Journal impact factor: 7.6 Number of times cited: 0
3. Velazquez R, Meechoovet B, Ow A, Foley C, Shaw A, Smith B, Oddo S, Hulme C, Dunckley T. Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice. *Mol Neurobiol. 2019 Jun 25. doi: 10.1007/s12035-019-01684-9. [Epub ahead of print]*
**Journal impact factor: 5.076 Number of times cited: 0
4. Velazquez R, Ferreira E, Winslow W, Dave N, Piras I, Naymik M, Huentelman MJ, Tran A, Caccamo A, and Oddo S. Maternal choline supplementation ameliorates Alzheimer's disease pathology by reducing brain homocysteine levels across multiple generations. *Mol Psychiatry. 2019 Jan 8.*
**Journal impact factor: 14.49 Number of times cited: 0
5. Belfiore R, Rodin A, Ferreira E, Velazquez R, Branca C, Caccamo A, Oddo S. Temporal and regional progression of Alzheimer's disease-like pathology in 3xTg-AD mice. *Aging Cell. 2019 Feb;18(1):e12873.*
**Journal impact factor: 6.7 Number of times cited: 3
6. Velazquez R, Ferreira E, Tran A, Turner EC, Belfiore R, Branca C, and Oddo S. Acute tau knockdown in the hippocampus of adult mice causes learning and memory deficits. *Aging Cell. 2018 May 10:e12775. doi: 10.1111/accel.12775.*
**Journal impact factor: 6.7 Number of times cited: 9
7. Caccamo A, Belfiore R, Oddo S. Genetically reducing mTOR signaling rescues central insulin dysregulation in a mouse model of Alzheimer's disease. *Neurobiol Aging. 2018 Aug;68:59-67*
**Journal impact factor: 5.12 Number of times cited: 7
8. Branca C, Ferreira E, Nguyen TV, Doyle K, Caccamo A, Oddo S. Genetic reduction of Nrf2 exacerbates cognitive deficits in a mouse model of Alzheimer's disease. *Hum Mol Genet. 2017 Dec 15;26(24):4823-4835.*
**Journal impact factor: 5.34 Number of times cited: 12
9. Caccamo A, Branca C, Piras IS, Ferreira E, Huentelman MJ, Liang WS, Readhead B, Dudley JT, Spangenberg EE, Green KN, Belfiore R, Winslow W, Oddo S. Necroptosis activation in Alzheimer's disease. *Nature Neuroscience. 2017, Sep;20(9):1236-1246.*
**Journal impact factor: 17.84 Number of times cited: 42

10. Velazquez A, Tran A, Ishimwe E, Denner L, Dave N, Oddo S[#], Dineley KT[#]. Central insulin dysregulation and energy dyshomeostasis in two models of Alzheimer's disease. *Neurobiol Aging*. 2017 Oct;58:1-13.
 **Journal impact factor: 5.12 Number of times cited: 15
 # Co-senior authors

11. Branca C, Shaw DM, Belfiore R, Gokhale V, Shaw AY, Foley C, Smith B, Hulme C, Dunckley T, Meechoovet B, Caccamo A, and Oddo S. Dyrk1 inhibition improves Alzheimer's disease-like pathology. *Aging Cell*. 2017 Oct;16(5):1146-1154.
 **Journal impact factor: 6.71 Number of times cited: 16

12. Branca C and Oddo S. Paving the way for new clinical trials for Alzheimer's disease. *Biological Psychiatry*. 2017 Jan 15;81(2):88-89.
 **Journal impact factor: 11.21 Number of times cited: 1

13. Norambuena A, Wallrabe H, McMahan L, Silva A, Swanson E, Khan SS, Baerthlein D, Kodis E, Oddo S, Mandell JW, Bloom GS. mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer's disease. *Alzheimers Dement*. 2017 Feb;13(2):152-167.
 **Journal impact factor: 11.62 Number of times cited: 20

14. Caccamo A, Ferreira E, Branca C, Oddo S. p62 improves AD-like pathology by increasing autophagy. *Mol Psychiatry*. 2017 Jun;22(6):865-873.
 **Journal impact factor: 14.49 Number of times cited: 31

15. Velazquez R, Shaw DM, Caccamo A, Oddo S. Pim 1 inhibition as a novel therapeutic strategy for Alzheimer's disease. *Mol Neurodegener*. 2016 Jul 13;11(1):52.
 **Journal impact factor: 6.5 Number of times cited: 11

16. Ferreira E, Shaw DM, Oddo S. Identification of learning-induced changes in protein networks in the hippocampi of a mouse model of Alzheimer's disease. *Transl Psychiatry*. 2016 Jul 5;6(7):e849.
 **Journal impact factor: 5.6 Number of times cited: 1

17. Caccamo A, Branca C, Talboom JS, Shaw DM, Turner D, Ma L, Messina A, Huang Z, We J, Oddo S. Reducing ribosomal protein S6 kinase 1 expression improves spatial memory and synaptic plasticity in a mouse model of Alzheimer's disease. *J Neurosci*. 2015 Oct 14;35(41):14042-56.
 **Journal impact factor: 6.3 Number of times cited: 42

18. Talboom JS, Velazquez R, Oddo S. The mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer's disease. *NPJ Aging Mech Dis*. 2015 Oct 15;1:15008. doi: 10.1038/npjamd.2015.8.
 **Journal impact factor: N/A Number of times cited: 12

19. Mastroeni D, Delvaux E, Nolz J, Tan Y, Grover, A, Oddo S, Coleman P. Aberrant Intracellular Localization of H3k4me3 Demonstrates an Early Epigenetic Phenomenon in Alzheimer's Disease. *Neurobiol Aging*. 2015 Dec;36(12):3121-9.
**Journal impact factor: 5.013 Number of times cited: 20
20. Caccamo A, Shaw DM, Guarino F, Messina A, Walker AW, Oddo S. Reduced protein turnover mediates functional deficits in transgenic mice expressing the 25 kDa C-terminal fragment of TDP-43. *Hum Mol Genet*. 2015 Aug 15;24(16):4625-35.
**Journal impact factor: 6.3 Number of times cited: 16
21. Richardson A, Galvan V, Lin AL, Oddo S. How Longevity Research Can Lead to Therapies for Alzheimer's Disease: The Rapamycin Story. *Exp Gerontol*. 2015 Aug;68:51-8.
**Journal impact factor: 3.529 Number of times cited: 65
22. Branca C, Wisely EV, Hartman LK, Caccamo A, Oddo S. Administration of a selective β 2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease. *Neurobiol of Aging*. 2014 Dec;35(12):2726-35.
**Journal impact factor: 6.189 Number of times cited: 32
23. Caccamo A, De Pinto V, Messina A, Branca C, Oddo S. Genetic reduction of mTOR ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature. *J Neurosci*. 2014 Jun 4;34(23):7988-98.
**Journal impact factor: 6.9 Number of times cited: 93
24. Wisely EV, Xiang YK, Oddo S. Genetic suppression of β 2-adrenergic receptors ameliorates tau pathology in a mouse model of tauopathies. *Hum Mol Genet*. 2014 Aug 1;23(15):4024-34.
**Journal impact factor: 7.692 Number of times cited: 17
25. Orr ME, Salinas A, Buffenstein R, Oddo S. Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer's disease pathology. *Neurobiol Aging*. 2014 Jun;35(6):1233-42.
**Journal impact factor: 6.189 Number of times cited: 46
26. Edrey YH, Oddo S, Cornelius C, Caccamo A, Calabrese V, Buffenstein R. Oxidative damage and amyloid- β metabolism in brain regions of the longest-lived rodents. *J Neurosci Res*. 2014 Feb;92(2):195-205.
**Journal impact factor: 2.974 Number of times cited: 25
27. Orr ME and Oddo S. Autophagic/lysosomal dysfunction in Alzheimer's disease. *Alzheimers Res Ther*. 2013 Oct 29;5(5):53.
**Journal impact factor: 4.390 Number of times cited: 75
28. Medina DX, Orr ME, Oddo S. Accumulation of C-terminal fragments of TDP-43 leads to synaptic loss and cognitive deficits in human TDP-43 transgenic mice. *Neurobiol Aging*. 2014 Jan;35(1):79-87.
**Journal impact factor: 6.189 Number of times cited: 23

29. Edrey YH, Medina DX, Gaczynska M, Osmulski PA, Oddo S, Caccamo A, Buffenstein R. Amyloid beta and the longest-lived rodent: the naked mole-rat as a model for natural protection from Alzheimer's disease. *Neurobiol Aging*. 2013 Oct;34(10):2352-60.
**Journal impact factor: 6.189 Number of times cited: 32
30. Caccamo A, Magri A, Medina DX, Wisely EV, Lopez-Aranda MF, Silva AJ, Oddo S. mTOR regulates tau phosphorylation and degradation: Implications for Alzheimer's disease and other tauopathies. *Aging Cell*. 2013 Jun;12(3):370-80.
**Journal impact factor: 7.15 Number of times cited: 194
31. Wang D, Fu Q, Zhou Y, Xu B, Shi Q, Igwe B, Matt L, Hell JW, Wisely EV, Oddo S, Xiang YK. β 2 adrenergic receptor, protein kinase A (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways mediate tau pathology in Alzheimer's disease models. *J Biol Chem*. 2013 Apr 12;288(15):10298-307.
**Journal impact factor: 4.773 Number of times cited: 54
32. Caccamo A, Medina DX, Oddo S. Glucocorticoids exacerbate cognitive deficits in TDP-25 transgenic mice via a glutathione-mediated mechanism: Implications for aging, stress and TDP-43 proteinopathies. *J Neurosci*. 2013 Jan 16;33(3):906-13.
**Journal impact factor: 7.115 Number of times cited: 26
33. Yan XX, Cai Y, Shelton J, Deng SH, Luo XG, Oddo S, LaFerla FM, Cai H, Rose GM, Patrylo PR. Chronic Temporal Lobe Epilepsy Is Associated with Enhanced Alzheimer-Like Neuropathology in 3xTg-AD Mice. *PLoS One*. 2012;7(11):e48782.
**Journal impact factor: 4.092 Number of times cited: 30
34. Klionsky DJ, Abdalla FC, Abeliovich H, Oberley TD, Oddo S, Ogawa M, ... Zuckerbraun B. Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy*. 2012 April. 8(4):445-544.
**Journal impact factor: 7.453 Number of times cited: 5,164
35. Takamura A, Sato Y, Watabe D, Okamoto Y, Nakata T, Kawarabayashi T, Oddo S, LaFerla FM, Shoji M, Matsubara E. Sortilin is required for toxic action of A β oligomers (A β O $_s$): Extracellular A β O $_s$ trigger apoptosis, and intraneuronal A β O $_s$ impair degradation pathways. *Life Sci*. 2012 Dec 10;91(23-24):1177-86.
**Journal impact factor: 2.451 Number of times cited: 26
36. Walker MP, LaFerla FM, Oddo S, Brewer GJ. Reversible epigenetic histone modifications and Bdnf expression in neurons with aging and from a mouse model of Alzheimer's disease. *Age (Dordr)*. 2013 Jun;35(3):519-31.
**Journal impact factor: 6.28 Number of times cited: 60
37. Cotella D, Hernandez Enriquez B, Wu X, Li R, Pan Z, Leveille J, Link C, Oddo S, and Sesti F. Toxic role of K $^+$ channel oxidation in mammalian brain (in press). *J Neurosci*. 2012 Mar 21;32(12):4133-4144.
**Journal impact factor: 7.27 Number of times cited: 59

38. Majumder S, Caccamo A, Medina DX, Benavides AD, Javors MA, Kraig E, Strong R, Richardson A, Oddo S. Life-long rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1 β and NMDA signaling. *Aging Cell*. 2012 Apr;11(2):326-35.
**Journal impact factor: 7.15 Number of times cited: 125
39. Oddo S. The role of mTOR signaling in Alzheimer disease. *Frontiers in Bioscience (Schol Ed)*. 2012 Jan 1;4:941-52.
**Journal impact factor: 4.05 Number of times cited: 90
40. Caccamo A, Majumder S, Oddo S. Cognitive decline typical of FTLD in transgenic mice expressing the 25-kDa C-terminal fragment of TDP-43. *Am J Pathol*. 2012 Jan;180(1):293-302. Epub 2011 Nov 7.
**Journal impact factor: 5.22 Number of times cited: 40
41. Majumder S, Richardson A, Strong R, Oddo S. Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. *PLoS One*. 2011;6(9):e25416. Epub 2011 Sep 28.
**Journal impact factor: 4.41 Number of times cited: 239
42. Cai Y, Zhang XM, Macklin LN, Cai H, Luo XG, Oddo S, LaFerla FM, Struble RG, Rose GM, Patrylo PR, Yan XX. BACE1 Elevation is Involved in Amyloid Plaque Development in the Triple Transgenic Model of Alzheimer's Disease: Differential A β Antibody Labeling of Early-Onset Axon Terminal Pathology. *Neurotox Res*. 2012 Feb;21(2):160-74. Epub 2011 Jul 2.
**Journal impact factor: 3.01 Number of times cited: 46
43. Bianchi FT, Camera P, Ala U, Imperiale D, Migheli A, Boda E, Tempia F, Berto G, Bosio Y, Oddo S, LaFerla FM, Taraglio S, Dotti CG, Di Cunto F. The Collagen Chaperone HSP47 Is a New Interactor of APP that Affects the Levels of Extracellular Beta-Amyloid Peptides. *PLoS One*. 2011 Jul;6(7):22370-22370.
**Journal impact factor: 4.41 Number of times cited: 14
44. Caccamo A, Maldonado MA, Majumder S, Medina DX, Holbein W, Magr A, Oddo S. Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. *J Biol Chem*. 2011 Mar;286(11):8924-8932.
**Journal impact factor: 5.33 Number of times cited: 116
45. Medina DX, Caccamo A, Oddo S. Methylene blue reduces A β levels and rescues early cognitive deficit by increasing proteasome activity. *Brain Pathol*. 2011 Mar;21(2):140-149.
**Journal impact factor: 4.74 Number of times cited: 167
46. Caccamo A, Maldonado MA, Bokov AF, Majumder S, Oddo S. CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease. *Proc Natl Acad Sci U S A*. 2010 Dec;107(52):22687-22692.
**Journal impact factor: 9.77 Number of times cited: 177

47. Caccamo A, Magrí A, Oddo S. Age-dependent changes in TDP-43 levels in a mouse model of Alzheimer disease are linked to A β oligomers accumulation. *Mol Neurodegener*. 2010 Nov;5:51-51.
**Journal impact factor: 5.36 Number of times cited: 27
48. Nakashima AS, Oddo S, LaFerla FM, Dyck RH. Experience-dependent regulation of vesicular zinc in male and female 3xTg-AD mice. *Neurobiol Aging*. 2010 Apr;31(4):605-613.
**Journal impact factor: 6.63 Number of times cited: 12
49. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. *J Biol Chem*. 2010 Apr;285(17):13107-13120.
**Journal impact factor: 5.33 Number of times cited: 549
50. Bryleva EY, Rogers MA, Chang CC, Buen F, Harris BT, Rousset E, Seidah NG, Oddo S, LaFerla FM, Spencer TA, Hickey WF, Chang TY. ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. *Proc Natl Acad Sci U S A*. 2010 Feb;107(7):3081-3086.
**Journal impact factor: 9.77 Number of times cited: 124
51. Caccamo A, Majumder S, Deng JJ, Bai Y, Thornton FB, Oddo S. Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability. *J Biol Chem*. 2009 Oct;284(40):27416-27424.
**Journal impact factor: 5.33 Number of times cited: 126
52. Oddo S, Caccamo A, Cheng D, LaFerla FM. Genetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathology. *Brain Pathol*. 2009 Jul;19(3):421-430.
**Journal impact factor: 4.74 Number of times cited: 32
53. Ouellet M, Emond V, Chen CT, Julien C, Bourasset F, Oddo S, LaFerla F, Bazinet RP, Calon F. Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: An in situ cerebral perfusion study. *Neurochem Int*. 2009 Dec;55(7):476-82. Epub 2009 May 13.
**Journal impact factor: 3.60 Number of times cited: 149
54. Guan H, Liu Y, Daily A, Police S, Kim MH, Oddo S, LaFerla FM, Pauly JR, Murphy MP, Hersh LB. Peripherally expressed neprilysin reduces brain amyloid burden: A novel approach for treating Alzheimer's disease. *J Neurosci Res*. 2009 May;87(6):1462-1473.
**Journal impact factor: 2.96 Number of times cited: 72
55. McAlpine FE, Lee JK, Harms AS, Ruhn KA, Blurton-Jones M, Hong J, Das P, Golde TE, LaFerla FM, Oddo S, Blesch A, Tansey MG. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. *Neurobiol Dis*. 2009 Apr;34(1):163-177.
**Journal impact factor: 5.12 Number of times cited: 196

56. Bourasset F, Mélissa O, Tremblay C, Julien C, Do TM, Oddo S, LaFerla F, Calon F. Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease. *Neuropharmacology*. 2009 Mar;56(4):808-813.
**Journal impact factor: 4.68 Number of times cited: 68
57. Nuntagij P, Oddo S, LaFerla FM, Kotchabhakdi N, Ottersen OP, Torp R. Amyloid deposits show complexity and intimate spatial relationship with dendrosomatic plasma membranes: an electron microscopic 3D reconstruction analysis in 3xTg-AD mice and aged canine. *J Alzheimers Dis*. 2009 Feb;16(2):315-323.
**Journal impact factor: 4.26 Number of times cited: 17
58. Gulinello M, Gertner M, Mendoza G, Schoenfeld BP, Oddo S, LaFerla F, Choi CH, McBride SM, Faber DS. Validation of a 2-day water maze protocol in mice. *Behav Brain Res*. 2009 Jan;196(2):220-227.
**Journal impact factor: 3.34 Number of times cited: 73
59. Janelins MC, Mastrangelo MA, Park KM, Sudol KL, Narrow WC, Oddo S, LaFerla FM, Callahan LM, Federoff HJ, Bowers WJ. Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. *Am J Pathol*. 2008 Dec;173(6):1768-1782.
**Journal impact factor: 5.22 Number of times cited: 140
60. Oddo S, Caccamo A, Tseng B, Cheng D, Vasilevko V, Cribbs DH, LaFerla FM. Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. *J Neurosci*. 2008 Nov;28(47):12163-12175.
**Journal impact factor: 7.27 Number of times cited: 119
61. Rodríguez JJ, Jones VC, Tabuchi M, Allan SM, Knight EM, LaFerla FM, Oddo S, Verkhratsky A. Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. *PLoS One*. 2008 Aug;3(8):2935.
**Journal impact factor: 4.41 Number of times cited: 276
62. Lopez JR, Lyckman A, Oddo S, LaFerla FM, Querfurth HW, Shtifman A. Increased intraneuronal resting [Ca²⁺] in adult Alzheimer's disease mice. *J Neurochem*. 2008 Apr;105(1):262-271.
**Journal impact factor: 4.38 Number of times cited: 122
63. Oddo S. The ubiquitin-proteasome system in Alzheimer's disease. *J Cell Mol Med*. 2008 Apr;12(2):363-373.
**Journal impact factor: 4.60 Number of times cited: 193
64. McKee AC, Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, LaFerla FM, Jenkins BG, Kowall NW, Dedeoglu A. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. *Brain Res*. 2008 May 1;1207:225-36. Epub 2008 Feb 16.
**Journal impact factor: 2.62 Number of times cited: 198

65. Maezawa I, Hong HS, Liu R, Wu CY, Cheng RH, Kung MP, Kung HF, Lam KS, Oddo S, LaFerla FM, Jin LW. Congo red and thioflavin-T analogs detect Abeta oligomers. *J Neurochem*. 2008 Jan;104(2):457-468.
**Journal impact factor: 4.38 Number of times cited: 177
66. Giménez-Llort L, Blázquez G, Cañete T, Johansson B, Oddo S, Tobeña A, LaFerla FM, Fernández-Teruel A. Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid. *Neurosci Biobehav Rev*. 2007;31(1):125-47.
**Journal impact factor: 9.01 Number of times cited: 193
67. Carroll JC, Rosario ER, Chang L, Stanczyk FZ, Oddo S, LaFerla FM, Pike CJ. Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. *J Neurosci*. 2007 Nov;27(48):13357-13365.
**Journal impact factor: 7.27 Number of times cited: 247
68. Cole AR, Noble W, van Aalten L, Plattner F, Meimaridou R, Hogan D, Taylor M, LaFrancois J, Gunn-Moore F, Verkhatsky A, Oddo S, LaFerla F, Giese KP, Dineley KT, Duff K, Richardson JC, Yan SD, Hanger DP, Allan SM, Sutherland C. Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. *J Neurochem*. 2007 Nov;103(3):1132-1144.
**Journal impact factor: 4.38 Number of times cited: 140
69. Yamasaki TR, Blurton-Jones M, Morrisette DA, Kitazawa M, Oddo S, LaFerla FM. Neural stem cells improve memory in an inducible mouse model of neuronal loss. *J Neurosci*. 2007 Oct;27(44):11925-11933.
**Journal impact factor: 7.27 Number of times cited: 170
70. Clinton LK, Billings LM, Green KN, Caccamo A, Ngo J, Oddo S, McGaugh JL, LaFerla FM. Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. *Neurobiol Dis*. 2007 Oct;28(1):76-82.
**Journal impact factor: 5.12 Number of times cited: 202
71. Oddo S, Caccamo A, Cheng D, Jouleh B, Torp R, LaFerla FM. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice. *J Neurochem*. 2007 Aug;102(4):1053-1063.
**Journal impact factor: 4.38 Number of times cited: 86
72. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. *Nat Rev Neurosci*. 2007 Jul;8(7):499-509.
**Journal impact factor: 29.51 Number of times cited: 1,623
73. Caccamo A, Oddo S, Tran LX, LaFerla FM. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. *Am J Pathol*. 2007 May;170(5):1669-1675.
**Journal impact factor: 5.22 Number of times cited: 171

74. Stutzmann GE, Smith I, Caccamo A, Oddo S, Parker I, LaFerla F. Enhanced ryanodine-mediated calcium release in mutant PS1-expressing Alzheimer's mouse models. *Ann N Y Acad Sci*. 2007 Feb;1097:265-277.
**Journal impact factor: 2.85 Number of times cited: 103
75. Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, LaFerla FM. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. *J Biol Chem*. 2006 Dec;281(51):39413-39423.
**Journal impact factor: 5.33 Number of times cited: 323
76. Rosario ER, Carroll JC, Oddo S, LaFerla FM, Pike CJ. Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer's disease. *J Neurosci*. 2006 Dec;26(51):13384-13389.
**Journal impact factor: 7.27 Number of times cited: 134
77. Stutzmann GE, Smith I, Caccamo A, Oddo S, LaFerla FM, Parker I. Enhanced ryanodine receptor recruitment contributes to Ca²⁺ disruptions in young, adult, and aged Alzheimer's disease mice. *J Neurosci*. 2006 May;26(19):5180-5189.
**Journal impact factor: 7.27 Number of times cited: 258
78. Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. *Neuron*. 2006 Mar;49(5):671-682.
**Journal impact factor: 14.03 Number of times cited: 393
79. Oddo S, LaFerla FM. The role of nicotinic acetylcholine receptors in Alzheimer's disease. *J Physiol Paris*. 2006 Mar;99(2-3):172-179.
**Journal impact factor: 3.03 Number of times cited: 132
80. Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, LaFerla FM. Temporal profile of amyloid-beta (Aβ) oligomerization in an in vivo model of Alzheimer disease. A link between Aβ and tau pathology. *J Biol Chem*. 2006 Jan;281(3):1599-1604.
**Journal impact factor: 5.33 Number of times cited: 424
81. Oddo S, Caccamo A, Smith IF, Green KN, LaFerla FM. A dynamic relationship between intracellular and extracellular pools of Aβ. *Am J Pathol*. 2006 Jan;168(1):184-194.
**Journal impact factor: 5.22 Number of times cited: 226
82. Janelisins MC, Mastrangelo MA, Oddo S, LaFerla FM, Federoff HJ, Bowers WJ. Early correlation of microglial activation with enhanced tumor necrosis factor-α and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. *J Neuroinflammation*. 2005 Oct;2:23-23.
**Journal impact factor: 5.79 Number of times cited: 208
83. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. *J Neurosci*. 2005 Sep;25(39):8843-8853.
**Journal impact factor: 7.27 Number of times cited: 514

84. Smith IF, Hitt B, Green KN, Oddo S, LaFerla FM. Enhanced caffeine-induced Ca²⁺ release in the 3xTg-AD mouse model of Alzheimer's disease. *J Neurochem*. 2005 Sep;94(6):1711-1718.
**Journal impact factor: 4.38 Number of times cited: 146
85. Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM. Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. *Neurobiol Aging*. 2005 May;26(5):645-654.
**Journal impact factor: 5.12 Number of times cited: 315
86. LaFerla FM, Oddo S. Alzheimer's disease: Abeta, tau and synaptic dysfunction. *Trends Mol Med*. 2005 Apr;11(4):170-176.
**Journal impact factor: 10.31 Number of times cited: 412
87. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. *Neuron*. 2005 Mar;45(5):675-688.
**Journal impact factor: 14.03 Number of times cited: 1,112
88. Oddo S, Caccamo A, Green KN, Liang K, Tran L, Chen Y, Leslie FM, LaFerla FM. Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. *Proc Natl Acad Sci U S A*. 2005 Feb;102(8):3046-3051.
**Journal impact factor: 9.77 Number of times cited: 208
89. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. *Neuron*. 2004 Aug;43(3):321-332.
**Journal impact factor: 14.03 Number of times cited: 842
90. Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, LaFerla FM, Rohn TT, Cotman CW. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. *J Clin Invest*. 2004 Jul;114(1):121-130.
**Journal impact factor: 14.15 Number of times cited: 476
91. Shakkottai VG, Chou CH, Oddo S, Sailer CA, Knaus HG, Gutman GA, Barish ME, LaFerla FM, Chandy KG. Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia. *J Clin Invest*. 2004 Feb;113(4):582-590.
**Journal impact factor: 14.15 Number of times cited: 91
92. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. *Neurobiol Aging*. 2003 Dec;24(8):1063-1070.
**Journal impact factor: 6.63 Number of times cited: 872
93. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kaye R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. *Neuron*. 2003 Jul;39(3):409-421.
**Journal impact factor: 14.03 Number of times cited: 3,158

94. Sugarman MC, Yamasaki TR, Oddo S, Echevoyen JC, Murphy MP, Golde TE, Jannatipour M, Leissring MA, LaFerla FM. Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci U S A. 2002 Apr;99(9):6334-6339.

**Journal impact factor: 9.77 Number of times cited: 122

BOOKS, MONOGRAPHS, CHAPTERS

1. Oddo S and Kitazawa M. Genetically modified rodent models: a new generation of translational cognitive science. The Maze Book, edited by Heather Bimonte-Nelson. Humana Press; 2015. p. 259 – 283.
2. Oddo S. Animal models of Alzheimer's disease: Plaques, tangles and memory decline. In: A multidisciplinary approach to dissect the Alzheimer Pathology, edited by Roberto Dominici and Ida Biunno. Transworld Research Network; 2008. p. 79 - 82.
3. Oddo S. and LaFerla FM. Amyloid plaques and neurofibrillary tangles in a triple transgenic model: qualitative similarities with human Alzheimer's neuropathology. In: Recent progress in Alzheimer's and Parkinson's diseases, edited by Israel Hanin, Ramon Cacabelos, and Abraham Fisher. Taylor & Francis; 2005. p. 111 - 116.

PUBLICATIONS:

PEER-REVIEWED ARTICLES

Google Scholar Citation Indexes: Total Citations: 24,332; **h-index 59**:

https://scholar.google.com/citations?hl=en&user=OXHDKSwAAAAJ&view_op=list_works&sortby=pubdate

Peer-Reviewed Research Articles (total 94)

The impact factors are reported for the year when the article was published and were obtained from the Journal home page. The number of citations were obtained from Google Scholar and last accessed on March 25, 2019.

1. Vartak RS, Rodin A, Oddo S. Differential activation of the mTOR/autophagy pathway predicts cognitive performance in APP/PS1 mice. *Neurobiol Aging*. *in press*.
**Journal impact factor: 5.153 Number of times cited: 0
2. Velazquez R, Ferreira E, Knowles S, Fux C, Rodin A, Winslow W, Oddo S. Lifelong choline supplementation ameliorates Alzheimer's disease pathology and associated cognitive deficits by attenuating microglia activation. *Aging Cell*. 2019 Sep 27:e13037
**Journal impact factor: 7.6 Number of times cited: 0
3. Velazquez R, Meechoovet B, Ow A, Foley C, Shaw A, Smith B, Oddo S, Hulme C, Dunckley T. Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice. *Mol Neurobiol*. 2019 Jun 25. doi: 10.1007/s12035-019-01684-9. [Epub ahead of print]
**Journal impact factor: 5.076 Number of times cited: 0
4. Velazquez R, Ferreira E, Winslow W, Dave N, Piras I, Naymik M, Huentelman MJ, Tran A, Caccamo A, and Oddo S. Maternal choline supplementation ameliorates Alzheimer's disease pathology by reducing brain homocysteine levels across multiple generations. *Mol Psychiatry*. 2019 Jan 8.
**Journal impact factor: 14.49 Number of times cited: 0
5. Belfiore R, Rodin A, Ferreira E, Velazquez R, Branca C, Caccamo A, Oddo S. Temporal and regional progression of Alzheimer's disease-like pathology in 3xTg-AD mice. *Aging Cell*. 2019 Feb;18(1):e12873.
**Journal impact factor: 6.7 Number of times cited: 3
6. Velazquez R, Ferreira E, Tran A, Turner EC, Belfiore R, Branca C, and Oddo S. Acute tau knockdown in the hippocampus of adult mice causes learning and memory deficits. *Aging Cell*. 2018 May 10:e12775. doi: 10.1111/accel.12775.
**Journal impact factor: 6.7 Number of times cited: 9
7. Caccamo A, Belfiore R, Oddo S. Genetically reducing mTOR signaling rescues central insulin dysregulation in a mouse model of Alzheimer's disease. *Neurobiol Aging*. 2018 Aug;68:59-67
**Journal impact factor: 5.12 Number of times cited: 7
8. Branca C, Ferreira E, Nguyen TV, Doyle K, Caccamo A, Oddo S. Genetic reduction of Nrf2 exacerbates cognitive deficits in a mouse model of Alzheimer's disease. *Hum Mol Genet*. 2017 Dec 15;26(24):4823-4835.

**Journal impact factor: 5.34 Number of times cited: 12

9. Caccamo A, Branca C, Piras IS, Ferreira E, Huentelman MJ, Liang WS, Readhead B, Dudley JT, Spangenberg EE, Green KN, Belfiore R, Winslow W, Oddo S. Necroptosis activation in Alzheimer's disease. *Nature Neuroscience*. 2017, Sep;20(9):1236-1246.

**Journal impact factor: 17.84 Number of times cited: 42

10. Velazquez A, Tran A, Ishimwe E, Denner L, Dave N, Oddo S[#], Dineley KT[#]. Central insulin dysregulation and energy dyshomeostasis in two models of Alzheimer's disease. *Neurobiol Aging*. 2017 Oct;58:1-13.

**Journal impact factor: 5.12 Number of times cited: 15

Co-senior authors

11. Branca C, Shaw DM, Belfiore R, Gokhale V, Shaw AY, Foley C, Smith B, Hulme C, Dunckley T, Meechoovet B, Caccamo A, and Oddo S. Dyrk1 inhibition improves Alzheimer's disease-like pathology. *Aging Cell*. 2017 Oct;16(5):1146-1154.

**Journal impact factor: 6.71 Number of times cited: 16

12. Branca C and Oddo S. Paving the way for new clinical trials for Alzheimer's disease. *Biological Psychiatry*. 2017 Jan 15;81(2):88-89.

**Journal impact factor: 11.21 Number of times cited: 1

13. Norambuena A, Wallrabe H, McMahon L, Silva A, Swanson E, Khan SS, Baerthlein D, Kodis E, Oddo S, Mandell JW, Bloom GS. mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer's disease. *Alzheimers Dement*. 2017 Feb;13(2):152-167.

**Journal impact factor: 11.62 Number of times cited: 20

14. Caccamo A, Ferreira E, Branca C, Oddo S. p62 improves AD-like pathology by increasing autophagy. *Mol Psychiatry*. 2017 Jun;22(6):865-873.

**Journal impact factor: 14.49 Number of times cited: 31

15. Velazquez R, Shaw DM, Caccamo A, Oddo S. Pim 1 inhibition as a novel therapeutic strategy for Alzheimer's disease. *Mol Neurodegener*. 2016 Jul 13;11(1):52.

**Journal impact factor: 6.5 Number of times cited: 11

16. Ferreira E, Shaw DM, Oddo S. Identification of learning-induced changes in protein networks in the hippocampi of a mouse model of Alzheimer's disease. *Transl Psychiatry*. 2016 Jul 5;6(7):e849.

**Journal impact factor: 5.6 Number of times cited: 1

17. Caccamo A, Branca C, Talboom JS, Shaw DM, Turner D, Ma L, Messina A, Huang Z, We J, Oddo S. Reducing ribosomal protein S6 kinase 1 expression improves spatial memory and synaptic plasticity in a mouse model of Alzheimer's disease. *J Neurosci*. 2015 Oct 14;35(41):14042-56.

**Journal impact factor: 6.3 Number of times cited: 42

18. Talboom JS, Velazquez R, Oddo S. The mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer's disease. *NPJ Aging Mech Dis*. 2015 Oct 15;1:15008. doi: 10.1038/npjamd.2015.8.

**Journal impact factor: N/A Number of times cited: 12

19. Mastroeni D, Delvaux E, Nolz J, Tan Y, Grover, A, Oddo S, Coleman P. Aberrant Intracellular Localization of H3k4me3 Demonstrates an Early Epigenetic Phenomenon in Alzheimer's Disease. *Neurobiol Aging*. 2015 Dec;36(12):3121-9.
**Journal impact factor: 5.013 Number of times cited: 20
20. Caccamo A, Shaw DM, Guarino F, Messina A, Walker AW, Oddo S. Reduced protein turnover mediates functional deficits in transgenic mice expressing the 25 kDa C-terminal fragment of TDP-43. *Hum Mol Genet*. 2015 Aug 15;24(16):4625-35.
**Journal impact factor: 6.3 Number of times cited: 16
21. Richardson A, Galvan V, Lin AL, Oddo S. How Longevity Research Can Lead to Therapies for Alzheimer's Disease: The Rapamycin Story. *Exp Gerontol*. 2015 Aug;68:51-8.
**Journal impact factor: 3.529 Number of times cited: 65
22. Branca C, Wisely EV, Hartman LK, Caccamo A, Oddo S. Administration of a selective β 2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease. *Neurobiol of Aging*. 2014 Dec;35(12):2726-35.
**Journal impact factor: 6.189 Number of times cited: 32
23. Caccamo A, De Pinto V, Messina A, Branca C, Oddo S. Genetic reduction of mTOR ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature. *J Neurosci*. 2014 Jun 4;34(23):7988-98.
**Journal impact factor: 6.9 Number of times cited: 93
24. Wisely EV, Xiang YK, Oddo S. Genetic suppression of β 2-adrenergic receptors ameliorates tau pathology in a mouse model of tauopathies. *Hum Mol Genet*. 2014 Aug 1;23(15):4024-34.
**Journal impact factor: 7.692 Number of times cited: 17
25. Orr ME, Salinas A, Buffenstein R, Oddo S. Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer's disease pathology. *Neurobiol Aging*. 2014 Jun;35(6):1233-42.
**Journal impact factor: 6.189 Number of times cited: 46
26. Edrey YH, Oddo S, Cornelius C, Caccamo A, Calabrese V, Buffenstein R. Oxidative damage and amyloid- β metabolism in brain regions of the longest-lived rodents. *J Neurosci Res*. 2014 Feb;92(2):195-205.
**Journal impact factor: 2.974 Number of times cited: 25
27. Orr ME and Oddo S. Autophagic/lysosomal dysfunction in Alzheimer's disease. *Alzheimers Res Ther*. 2013 Oct 29;5(5):53.
**Journal impact factor: 4.390 Number of times cited: 75
28. Medina DX, Orr ME, Oddo S. Accumulation of C-terminal fragments of TDP-43 leads to synaptic loss and cognitive deficits in human TDP-43 transgenic mice. *Neurobiol Aging*. 2014 Jan;35(1):79-87.
**Journal impact factor: 6.189 Number of times cited: 23
29. Edrey YH, Medina DX, Gaczynska M, Osmulski PA, Oddo S, Caccamo A, Buffenstein R. Amyloid beta and the longest-lived rodent: the naked mole-rat as a model for natural protection from Alzheimer's disease. *Neurobiol Aging*. 2013 Oct;34(10):2352-60.
**Journal impact factor: 6.189 Number of times cited: 32

30. Caccamo A, Magri A, Medina DX, Wisely EV, Lopez-Aranda MF, Silva AJ, Oddo S. mTOR regulates tau phosphorylation and degradation: Implications for Alzheimer's disease and other tauopathies. *Aging Cell*. 2013 Jun;12(3):370-80.
**Journal impact factor: 7.15 Number of times cited: 194
31. Wang D, Fu Q, Zhou Y, Xu B, Shi Q, Igwe B, Matt L, Hell JW, Wisely EV, Oddo S, Xiang YK. β 2 adrenergic receptor, protein kinase A (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways mediate tau pathology in Alzheimer's disease models. *J Biol Chem*. 2013 Apr 12;288(15):10298-307.
**Journal impact factor: 4.773 Number of times cited: 54
32. Caccamo A, Medina DX, Oddo S. Glucocorticoids exacerbate cognitive deficits in TDP-25 transgenic mice via a glutathione-mediated mechanism: Implications for aging, stress and TDP-43 proteinopathies. *J Neurosci*. 2013 Jan 16;33(3):906-13.
**Journal impact factor: 7.115 Number of times cited: 26
33. Yan XX, Cai Y, Shelton J, Deng SH, Luo XG, Oddo S, LaFerla FM, Cai H, Rose GM, Patrylo PR. Chronic Temporal Lobe Epilepsy Is Associated with Enhanced Alzheimer-Like Neuropathology in 3xTg-AD Mice. *PLoS One*. 2012;7(11):e48782.
**Journal impact factor: 4.092 Number of times cited: 30
34. Klionsky DJ, Abdalla FC, Abeliovich H,Oberley TD, Oddo S, Ogawa M, ... Zuckerbraun B. Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy*. 2012 April. 8(4):445-544.
**Journal impact factor: 7.453 Number of times cited: 5,164
35. Takamura A, Sato Y, Watabe D, Okamoto Y, Nakata T, Kawarabayashi T, Oddo S, LaFerla FM, Shoji M, Matsubara E. Sortilin is required for toxic action of A β oligomers (A β O $_s$): Extracellular A β O $_s$ trigger apoptosis, and intraneuronal A β O $_s$ impair degradation pathways. *Life Sci*. 2012 Dec 10;91(23-24):1177-86.
**Journal impact factor: 2.451 Number of times cited: 26
36. Walker MP, LaFerla FM, Oddo S, Brewer GJ. Reversible epigenetic histone modifications and Bdnf expression in neurons with aging and from a mouse model of Alzheimer's disease. *Age (Dordr)*. 2013 Jun;35(3):519-31.
**Journal impact factor: 6.28 Number of times cited: 60
37. Cotella D, Hernandez Enriquez B, Wu X, Li R, Pan Z, Leveille J, Link C, Oddo S, and Sesti F. Toxic role of K $^+$ channel oxidation in mammalian brain (in press). *J Neurosci*. 2012 Mar 21;32(12):4133-4144.
**Journal impact factor: 7.27 Number of times cited: 59
38. Majumder S, Caccamo A, Medina DX, Benavides AD, Javors MA, Kraig E, Strong R, Richardson A, Oddo S. Life-long rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1 β and NMDA signaling. *Aging Cell*. 2012 Apr;11(2):326-35.
**Journal impact factor: 7.15 Number of times cited: 125
39. Oddo S. The role of mTOR signaling in Alzheimer disease. *Frontiers in Bioscience (Schol Ed)*. 2012 Jan 1;4:941-52.
**Journal impact factor: 4.05 Number of times cited: 90

40. Caccamo A, Majumder S, Oddo S. Cognitive decline typical of FTLD in transgenic mice expressing the 25-kDa C-terminal fragment of TDP-43. *Am J Pathol*. 2012 Jan;180(1):293-302. Epub 2011 Nov 7.
**Journal impact factor: 5.22 Number of times cited: 40
41. Majumder S, Richardson A, Strong R, Oddo S. Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. *PLoS One*. 2011;6(9):e25416. Epub 2011 Sep 28.
**Journal impact factor: 4.41 Number of times cited: 239
42. Cai Y, Zhang XM, Macklin LN, Cai H, Luo XG, Oddo S, LaFerla FM, Struble RG, Rose GM, Patrylo PR, Yan XX. BACE1 Elevation is Involved in Amyloid Plaque Development in the Triple Transgenic Model of Alzheimer's Disease: Differential A β Antibody Labeling of Early-Onset Axon Terminal Pathology. *Neurotox Res*. 2012 Feb;21(2):160-74. Epub 2011 Jul 2.
**Journal impact factor: 3.01 Number of times cited: 46
43. Bianchi FT, Camera P, Ala U, Imperiale D, Migheli A, Boda E, Tempia F, Berto G, Bosio Y, Oddo S, LaFerla FM, Taraglio S, Dotti CG, Di Cunto F. The Collagen Chaperone HSP47 Is a New Interactor of APP that Affects the Levels of Extracellular Beta-Amyloid Peptides. *PLoS One*. 2011 Jul;6(7):22370-22370.
**Journal impact factor: 4.41 Number of times cited: 14
44. Caccamo A, Maldonado MA, Majumder S, Medina DX, Holbein W, Magr A, Oddo S. Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. *J Biol Chem*. 2011 Mar;286(11):8924-8932.
**Journal impact factor: 5.33 Number of times cited: 116
45. Medina DX, Caccamo A, Oddo S. Methylene blue reduces A β levels and rescues early cognitive deficit by increasing proteasome activity. *Brain Pathol*. 2011 Mar;21(2):140-149.
**Journal impact factor: 4.74 Number of times cited: 167
46. Caccamo A, Maldonado MA, Bokov AF, Majumder S, Oddo S. CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease. *Proc Natl Acad Sci U S A*. 2010 Dec;107(52):22687-22692.
**Journal impact factor: 9.77 Number of times cited: 177
47. Caccamo A, Magr A, Oddo S. Age-dependent changes in TDP-43 levels in a mouse model of Alzheimer disease are linked to A β oligomers accumulation. *Mol Neurodegener*. 2010 Nov;5:51-51.
**Journal impact factor: 5.36 Number of times cited: 27
48. Nakashima AS, Oddo S, LaFerla FM, Dyck RH. Experience-dependent regulation of vesicular zinc in male and female 3xTg-AD mice. *Neurobiol Aging*. 2010 Apr;31(4):605-613.
**Journal impact factor: 6.63 Number of times cited: 12
49. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. *J Biol Chem*. 2010 Apr;285(17):13107-13120.
**Journal impact factor: 5.33 Number of times cited: 549

50. Bryleva EY, Rogers MA, Chang CC, Buen F, Harris BT, Rousselet E, Seidah NG, Oddo S, LaFerla FM, Spencer TA, Hickey WF, Chang TY. ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. *Proc Natl Acad Sci U S A*. 2010 Feb;107(7):3081-3086.
**Journal impact factor: 9.77 Number of times cited: 124
51. Caccamo A, Majumder S, Deng JJ, Bai Y, Thornton FB, Oddo S. Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability. *J Biol Chem*. 2009 Oct;284(40):27416-27424.
**Journal impact factor: 5.33 Number of times cited: 126
52. Oddo S, Caccamo A, Cheng D, LaFerla FM. Genetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathology. *Brain Pathol*. 2009 Jul;19(3):421-430.
**Journal impact factor: 4.74 Number of times cited: 32
53. Ouellet M, Emond V, Chen CT, Julien C, Bourasset F, Oddo S, LaFerla F, Bazinet RP, Calon F. Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: An in situ cerebral perfusion study. *Neurochem Int*. 2009 Dec;55(7):476-82. Epub 2009 May 13.
**Journal impact factor: 3.60 Number of times cited: 149
54. Guan H, Liu Y, Daily A, Police S, Kim MH, Oddo S, LaFerla FM, Pauly JR, Murphy MP, Hersh LB. Peripherally expressed neprilysin reduces brain amyloid burden: A novel approach for treating Alzheimer's disease. *J Neurosci Res*. 2009 May;87(6):1462-1473.
**Journal impact factor: 2.96 Number of times cited: 72
55. McAlpine FE, Lee JK, Harms AS, Ruhn KA, Blurton-Jones M, Hong J, Das P, Golde TE, LaFerla FM, Oddo S, Blesch A, Tansey MG. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. *Neurobiol Dis*. 2009 Apr;34(1):163-177.
**Journal impact factor: 5.12 Number of times cited: 196
56. Bourasset F, Mélissa O, Tremblay C, Julien C, Do TM, Oddo S, LaFerla F, Calon F. Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease. *Neuropharmacology*. 2009 Mar;56(4):808-813.
**Journal impact factor: 4.68 Number of times cited: 68
57. Nuntagij P, Oddo S, LaFerla FM, Kotchabhakdi N, Ottersen OP, Torp R. Amyloid deposits show complexity and intimate spatial relationship with dendrosomatic plasma membranes: an electron microscopic 3D reconstruction analysis in 3xTg-AD mice and aged canine. *J Alzheimers Dis*. 2009 Feb;16(2):315-323.
**Journal impact factor: 4.26 Number of times cited: 17
58. Gulinello M, Gertner M, Mendoza G, Schoenfeld BP, Oddo S, LaFerla F, Choi CH, McBride SM, Faber DS. Validation of a 2-day water maze protocol in mice. *Behav Brain Res*. 2009 Jan;196(2):220-227.
**Journal impact factor: 3.34 Number of times cited: 73
59. Janelins MC, Mastrangelo MA, Park KM, Sudol KL, Narrow WC, Oddo S, LaFerla FM, Callahan LM, Federoff HJ, Bowers WJ. Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. *Am J Pathol*. 2008 Dec;173(6):1768-1782.

**Journal impact factor: 5.22 Number of times cited: 140

60. Oddo S, Caccamo A, Tseng B, Cheng D, Vasilevko V, Cribbs DH, LaFerla FM. Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. *J Neurosci*. 2008 Nov;28(47):12163-12175.

**Journal impact factor: 7.27 Number of times cited: 119

61. Rodríguez JJ, Jones VC, Tabuchi M, Allan SM, Knight EM, LaFerla FM, Oddo S, Verkhratsky A. Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. *PLoS One*. 2008 Aug;3(8):2935.

**Journal impact factor: 4.41 Number of times cited: 276

62. Lopez JR, Lyckman A, Oddo S, LaFerla FM, Querfurth HW, Shtifman A. Increased intraneuronal resting [Ca²⁺] in adult Alzheimer's disease mice. *J Neurochem*. 2008 Apr;105(1):262-271.

**Journal impact factor: 4.38 Number of times cited: 122

63. Oddo S. The ubiquitin-proteasome system in Alzheimer's disease. *J Cell Mol Med*. 2008 Apr;12(2):363-373.

**Journal impact factor: 4.60 Number of times cited: 193

64. McKee AC, Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, LaFerla FM, Jenkins BG, Kowall NW, Dedeoglu A. Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. *Brain Res*. 2008 May 1;1207:225-36. Epub 2008 Feb 16.

**Journal impact factor: 2.62 Number of times cited: 198

65. Maezawa I, Hong HS, Liu R, Wu CY, Cheng RH, Kung MP, Kung HF, Lam KS, Oddo S, LaFerla FM, Jin LW. Congo red and thioflavin-T analogs detect Abeta oligomers. *J Neurochem*. 2008 Jan;104(2):457-468.

**Journal impact factor: 4.38 Number of times cited: 177

66. Giménez-Llort L, Blázquez G, Cañete T, Johansson B, Oddo S, Tobeña A, LaFerla FM, Fernández-Teruel A. Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: a role for intraneuronal amyloid. *NeurosciBiobehav Rev*. 2007;31(1):125-47.

**Journal impact factor: 9.01 Number of times cited: 193

67. Carroll JC, Rosario ER, Chang L, Stanczyk FZ, Oddo S, LaFerla FM, Pike CJ. Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. *J Neurosci*. 2007 Nov;27(48):13357-13365.

**Journal impact factor: 7.27 Number of times cited: 247

68. Cole AR, Noble W, van Aalten L, Plattner F, Meimaridou R, Hogan D, Taylor M, LaFrancois J, Gunn-Moore F, Verkhratsky A, Oddo S, LaFerla F, Giese KP, Dineley KT, Duff K, Richardson JC, Yan SD, Hanger DP, Allan SM, Sutherland C. Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. *J Neurochem*. 2007 Nov;103(3):1132-1144.

**Journal impact factor: 4.38 Number of times cited: 140

69. Yamasaki TR, Blurton-Jones M, Morrissette DA, Kitazawa M, Oddo S, LaFerla FM. Neural stem cells improve memory in an inducible mouse model of neuronal loss. *J Neurosci*. 2007 Oct;27(44):11925-11933.
**Journal impact factor: 7.27 Number of times cited: 170
70. Clinton LK, Billings LM, Green KN, Caccamo A, Ngo J, Oddo S, McGaugh JL, LaFerla FM. Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. *Neurobiol Dis*. 2007 Oct;28(1):76-82.
**Journal impact factor: 5.12 Number of times cited: 202
71. Oddo S, Caccamo A, Cheng D, Jouleh B, Torp R, LaFerla FM. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice. *J Neurochem*. 2007 Aug;102(4):1053-1063.
**Journal impact factor: 4.38 Number of times cited: 86
72. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. *Nat Rev Neurosci*. 2007 Jul;8(7):499-509.
**Journal impact factor: 29.51 Number of times cited: 1,623
73. Caccamo A, Oddo S, Tran LX, LaFerla FM. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. *Am J Pathol*. 2007 May;170(5):1669-1675.
**Journal impact factor: 5.22 Number of times cited: 171
74. Stutzmann GE, Smith I, Caccamo A, Oddo S, Parker I, LaFerla F. Enhanced ryanodine-mediated calcium release in mutant PS1-expressing Alzheimer's mouse models. *Ann N Y Acad Sci*. 2007 Feb;1097:265-277.
**Journal impact factor: 2.85 Number of times cited: 103
75. Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, LaFerla FM. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. *J Biol Chem*. 2006 Dec;281(51):39413-39423.
**Journal impact factor: 5.33 Number of times cited: 323
76. Rosario ER, Carroll JC, Oddo S, LaFerla FM, Pike CJ. Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer's disease. *J Neurosci*. 2006 Dec;26(51):13384-13389.
**Journal impact factor: 7.27 Number of times cited: 134
77. Stutzmann GE, Smith I, Caccamo A, Oddo S, LaFerla FM, Parker I. Enhanced ryanodine receptor recruitment contributes to Ca²⁺ disruptions in young, adult, and aged Alzheimer's disease mice. *J Neurosci*. 2006 May;26(19):5180-5189.
**Journal impact factor: 7.27 Number of times cited: 258
78. Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. *Neuron*. 2006 Mar;49(5):671-682.
**Journal impact factor: 14.03 Number of times cited: 393
79. Oddo S, LaFerla FM. The role of nicotinic acetylcholine receptors in Alzheimer's disease. *J Physiol Paris*. 2006 Mar;99(2-3):172-179.

**Journal impact factor: 3.03 Number of times cited: 132

80. Oddo S, Caccamo A, Tran L, Lambert MP, Glabe CG, Klein WL, LaFerla FM. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. *J Biol Chem*. 2006 Jan;281(3):1599-1604.

**Journal impact factor: 5.33 Number of times cited: 424

81. Oddo S, Caccamo A, Smith IF, Green KN, LaFerla FM. A dynamic relationship between intracellular and extracellular pools of Abeta. *Am J Pathol*. 2006 Jan;168(1):184-194.

**Journal impact factor: 5.22 Number of times cited: 226

82. Janelins MC, Mastrangelo MA, Oddo S, LaFerla FM, Federoff HJ, Bowers WJ. Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. *J Neuroinflammation*. 2005 Oct;2:23-23.

**Journal impact factor: 5.79 Number of times cited: 208

83. Kitazawa M, Oddo S, Yamasaki TR, Green KN, LaFerla FM. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. *J Neurosci*. 2005 Sep;25(39):8843-8853.

**Journal impact factor: 7.27 Number of times cited: 514

84. Smith IF, Hitt B, Green KN, Oddo S, LaFerla FM. Enhanced caffeine-induced Ca²⁺ release in the 3xTg-AD mouse model of Alzheimer's disease. *J Neurochem*. 2005 Sep;94(6):1711-1718.

**Journal impact factor: 4.38 Number of times cited: 146

85. Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM. Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. *Neurobiol Aging*. 2005 May;26(5):645-654.

**Journal impact factor: 5.12 Number of times cited: 315

86. LaFerla FM, Oddo S. Alzheimer's disease: Abeta, tau and synaptic dysfunction. *Trends Mol Med*. 2005 Apr;11(4):170-176.

**Journal impact factor: 10.31 Number of times cited: 412

87. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. *Neuron*. 2005 Mar;45(5):675-688.

**Journal impact factor: 14.03 Number of times cited: 1,112

88. Oddo S, Caccamo A, Green KN, Liang K, Tran L, Chen Y, Leslie FM, LaFerla FM. Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. *Proc Natl Acad Sci U S A*. 2005 Feb;102(8):3046-3051.

**Journal impact factor: 9.77 Number of times cited: 208

89. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. *Neuron*. 2004 Aug;43(3):321-332.

**Journal impact factor: 14.03 Number of times cited: 842

90. Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, LaFerla FM, Rohn TT, Cotman CW. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest. 2004 Jul;114(1):121-130.
**Journal impact factor: 14.15 Number of times cited: 476
91. Shakkottai VG, Chou CH, Oddo S, Sailer CA, Knaus HG, Gutman GA, Barish ME, LaFerla FM, Chandy KG. Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia. J Clin Invest. 2004 Feb;113(4):582-590.
**Journal impact factor: 14.15 Number of times cited: 91
92. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging. 2003 Dec;24(8):1063-1070.
**Journal impact factor: 6.63 Number of times cited: 872
93. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kaye R, Metherate R, Mattson MP, Akbari Y, LaFerla FM. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 2003 Jul;39(3):409-421.
**Journal impact factor: 14.03 Number of times cited: 3,158
94. Sugarman MC, Yamasaki TR, Oddo S, Echegoyen JC, Murphy MP, Golde TE, Jannatipour M, Leissring MA, LaFerla FM. Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci U S A. 2002 Apr;99(9):6334-6339.
**Journal impact factor: 9.77 Number of times cited: 122

Signed: 

Dated: March 5, 2020